(54) Title: USE OF GENETIC POLYMORPHISMS THAT ASSOCIATE WITH EFFICACY OF TREATMENT OF INFLAMMATORY DISEASE

(57) Abstract: The MHC III region of chromosome 6p21.3 harbors a DNA sequence, most likely within the TNF or LTA gene, which influences response to pimecrolimus for the treatment of atopic dermatitis. Accordingly, genetic polymorphisms in the TNF and LTA genes are useful as biomarkers of the efficacy of pimecrolimus treatment of inflammatory disease. By contrast, response to tacrolimus appears to be influenced by other biological pathways.
USE OF GENETIC POLYMORPHISMS THAT ASSOCIATE WITH
EFFICACY OF TREATMENT OF INFLAMMATORY DISEASE

FIELD OF THE INVENTION

[0001] This invention relates generally to the analytical testing of tissue samples in
vitro, and more particularly to the analysis of genetic polymorphisms as biomarkers for the
efficacy of treatments of inflammatory disease.

DESCRIPTION OF THE RELATED ART

[0002] Atopic dermatitis (AD), also known as eczema, is an inflammatory skin disease
typified by itchy inflamed skin that presents during infancy and childhood. The disease is
one of the most common dermatological disorders in Western countries, affecting as many
as 20% of children under the age of five. Cookson WO et al., Nature Genetics 27: 372-373

[0003] Pimecrolimus (Elidel®) is an ascomycin macrolactam derivative that was
specifically developed for the treatment of inflammatory skin diseases. Tacrolimus (FK506;
Protopic® or Prograf®) is a member of the same class of compounds and is also used to
treat inflammatory skin diseases. Both pimecrolimus and tacrolimus interfere with the
inflammatory process by binding with high affinity to macrophilin-12 and inhibiting
calcineurin, which blocks transcription of Th1- and Th2-type cytokines in T lymphocytes.
While the two compounds are structurally similar and have comparable mechanisms of
action, pimecrolimus has a higher affinity for skin than does tacrolimus.

[0004] It has long been recognized that there is a genetic basis to atopic diseases.
Several linkage analyses have been done to define susceptibility regions that contribute to
atopic dermatitis, as reviewed in Maclean JA & Eidelman FJ, Arch Dermatol 137:
1474-1476 (2001). At least five chromosomal regions (3q21, 5q31-33, 11q13, 13q12-14
and 14q11.2) are thought to contain atopic dermatitis susceptibility loci. Current thinking is
that atopic mechanisms are primarily responsible for the pathogenesis of the atopic
dermatitis. However, other genes involved with dermal inflammation may also contribute to

[0005] The response rate among patients taking topical macrolactams (pimecrolimus or
tacrolimus) is currently less than 50%. It is not known why some patients do not respond to
these medications. Thus, there remains a need in the art for the improving the efficacy of
topical macrolactams, such as by targeting appropriate formulations of the medications to those inflammatory disease patients who are genetically disposed to respond and benefit from the treatment.

SUMMARY OF THE INVENTION

[0006] The invention provides a method for treating atopic dermatitis, based upon a determination of the patient’s TNF alleles. In one embodiment, patients are tested for the presence of a (-1031) TNF polymorphism to determine what therapy is appropriate. Patients having the TT alleles (SEQ ID NO:1) at that locus are treated with pimecrolimus cream or ointment, while patients having the CC alleles (SEQ ID NO:2) or the CT alleles (SEQ ID NOS:1 and 2) are treated with a higher dose of pimecrolimus cream, with pimecrolimus cream plus another anti-inflammatory drug, or with an anti-inflammatory drug without pimecrolimus cream.

[0007] The invention also provides a general method for treating psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or any disorder for which pimecrolimus (oral, topical or other) is indicated, based upon a determination of the patient’s TNF alleles. In one embodiment, patients are tested for the presence of a (-1031) TNF polymorphism to determine what therapy is appropriate. Patients with TT alleles at that locus are treated with pimecrolimus, while patients with CC alleles and CT alleles are given a higher dose of pimecrolimus, pimecrolimus plus another anti-inflammatory drug or an anti-inflammatory drug without pimecrolimus.

[0008] The invention further provides a method for treating psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or any disorder for which pimecrolimus (oral, topical or other) is indicated, based upon a determination of the patient’s LTA alleles. In one embodiment, patients are tested for the presence of an ASN60THR LTA locus polymorphism to determine what therapy is appropriate. Patients with AA alleles (SEQ ID NO:3) or AC alleles (SEQ ID NOS:3 and 4) at that locus are treated with pimecrolimus, while patients with CC alleles (SEQ ID NO:4) are given a higher dose of pimecrolimus, pimecrolimus plus another anti-inflammatory drug or an anti-inflammatory drug without pimecrolimus.

[0009] The invention also provides a method for treating psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or any disorder for which tacrolimus (oral, topical or other) is indicated, based upon a determination of the patient’s CCR2
alleles. In one embodiment, patients are tested for the presence of a VAL64ILE CCR2 locus polymorphism to determine what therapy is appropriate. Patients with GG alleles (SEQ ID NO:5) at that locus are treated with tacrolimus, while patients with AG alleles (SEQ ID NOS:5 and 6) are given a higher dose of tacrolimus, tacrolimus plus another anti-inflammatory drug or an anti-inflammatory drug without tacrolimus.

[0010] The invention provides a method for treating atopic dermatitis or any disorder for which pimecrolimus (oral, topical or other) is indicated, where the level of TNF-α protein or mRNA present in the patient is measured prior to determining what therapy is appropriate. In one embodiment, when TNF-α protein or mRNA levels in the bodily fluids or non-inflamed tissue samples of the patient are low or normal, then the patient is treated with pimecrolimus. In another embodiment, when TNF-α protein or mRNA levels are elevated, then the patient is treated with pimecrolimus in combination with another anti-inflammatory drug or with an alternative therapy.

[0011] The invention further provides a method for determining a treatment strategy for a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus is indicated, said method comprises analyzing the level of TNF-α mRNA or TNF-α protein in a sample obtained from the subject, and wherein the treatment strategy comprises the selection of a pimecrolimus formulation as treatment when the level of TNF-α mRNA or TNF-α protein in the sample is low or normal; or the selection of either (A) a pimecrolimus formulation in combination with another immunosuppressant or (B) another immunosuppressant as treatment when the level of TNF-α mRNA or TNF-α protein in the sample is elevated. Preferably, said sample is taken from non-inflamed tissue.

[0012] The invention provides a method for choosing subjects for inclusion in a clinical trial of inflammatory skin disease or any other disorder for which pimecrolimus is indicated, where genetic polymorphisms at the (-1031) TNF locus, the ASN60THR LTA locus or the VAL64ILE CCR2 locus of the candidate subjects are interrogated prior to inclusion in the clinical trial.

[0013] The invention provides a kit for use in determining treatment strategy for a patient with inflammatory skin disease or any other disorder for which pimecrolimus is indicated. In one embodiment, the kit contains reagents for determining the levels of TNF-
α protein or mRNA in a sample obtained from a subject to be treated. In another embodiment, the kit contains reagents for determining the genotype of the subject in the TNF, LTA or CCR2 genes. The kit also contains a written product describing the use of the biomarker in determining a treatment strategy for the condition.

[0014] The invention further provides a method for determining a treatment strategy for a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus or tacrolimus is indicated, said method comprises analyzing the genotype of a subject at a genetic locus from the TNF gene cluster indicative of efficacy of a selected macrolactam formulation in treating the condition. Preferably, the genotype is determined by analyzing a sample obtained from said subject. In one embodiment, subjects / patients are tested for the presence of a (-1031) TNF polymorphism to determine the appropriate treatment strategy. For patients with TT alleles (SEQ ID NO:1) at that locus pimecrolimus is selected as treatment, while for patients with CC alleles (SEQ ID NO:2) and CT alleles (SEQ ID NOS:1 and 2) a higher dose of pimecrolimus, pimecrolimus plus another anti-inflammatory drug or an anti-inflammatory drug without pimecrolimus is selected as treatment. Another embodiment of the invention provides that said treatment strategy is based upon a determination of the patient’s LTA alleles. In a preferred embodiment, patients are tested for the presence of an ASN60THR LTA locus polymorphism to determine the treatment strategy. For patients with AA alleles (SEQ ID NO:3) or AC alleles (SEQ ID NOS:3 and 4) at that locus pimecrolimus is selected as treatment, while for patients with CC alleles (SEQ ID NO:4) a higher dose of pimecrolimus, pimecrolimus plus another anti-inflammatory drug or an anti-inflammatory drug without pimecrolimus is selected as treatment. The anti-inflammatory drug is preferably selected from the group consisting of hydrocortisone, cyclosporine, tacrolimus and sirolimus.

[0015] The invention provides a further method for determining a treatment strategy for a subject / patient affected by atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus or tacrolimus is indicated, based upon a determination of the patient’s CCR2 alleles. In one embodiment, the patient is tested for the presence of a VAL64ILE CCR2 locus polymorphism to determine the appropriate treatment strategy. For a patient with GG allele (SEQ ID NO:5) at that locus tacrolimus is selected as treatment strategy, while for a patient with AG allele
(SEQ ID NOS:5 and 6) a higher dose of tacrolimus, tacrolimus plus another anti-inflammatory drug or an anti-inflammatory drug without tacrolimus is selected as treatment strategy. The anti-inflammatory drug is preferably selected from the group consisting of hydrocortisone, cyclosporine, pimecrolimus and sirolimus.

[0016] The invention also provides the use of pimecrolimus in the manufacture of a medicament for the treatment of inflammatory disease in a selected patient population, wherein the patient population is selected on the basis of the genotype of the patients at a genetic locus from the TNF gene cluster indicative of efficacy of pimecrolimus in treating inflammatory disease. In one embodiment, the genotype of the selected patient population comprises the presence of a (-1031) TNF polymorphism. Preferably, the selected patient population comprises TT alleles at that locus. In another embodiment, the selected patient population comprises an ASN60THR LTA locus polymorphism. Preferably, the selected patient population comprises AA alleles or AC alleles at that locus.

[0017] Further, the invention provides the use of tacrolimus in the manufacture of a medicament for the treatment of inflammatory disease in a selected patient population, wherein the patient population is selected on the basis of the genotype of the patients at the CCR2 genetic locus indicative of efficacy of tacrolimus in treating inflammatory disease. In one embodiment, the selected patient population comprises the VAL64ILE CCR2 locus polymorphism. Preferably, said patient population comprise GG alleles at that locus.

[0018] The invention thus provides a way of improving the efficacy of topical macrolactams, particularly pimecrolimus, by identifying biomarkers of efficacy in the subjects to be treated and then targeting appropriate macrolactam formulations to those who are best able to respond and benefit from the treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIG. 1 is a diagrammatic representation of the major histocompatibility complex (MHC) on chromosome (Ch) 6 showing the placement of LTA (gene coding for lymphotoxin alpha) and TNF (gene coding for tumor necrosis factor alpha; TNF-α) within the MHC. Shown in greater detail below is the region of 6p21.3 that contains the TNF gene cluster. * denotes polymorphisms, which are roughly 2.5 kb apart, discussed herein. This figure is modified from Field M, *Q J Med* 94: 237-246 (2001).
DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] The efficacy of treatment of atopic dermatitis by pimecrolimus cream 1%, but not treatment by tacrolimus ointment 0.03%, is associated with polymorphic markers in the TNF cluster on 6p21.3. This discovery provides a way to use genetic polymorphisms that associate with the efficacy of pimecrolimus treatment in determining the most effective treatment.

[0021] The genetic locus was identified in a Phase IIIb trial that was designed as a head to head comparison of pimecrolimus cream 1% and tacrolimus ointment 0.03%. The six-week investigator-blinded trial of pediatric subjects with moderate atopic dermatitis explored the incidence of local application site reactions induced by the two topical macrolactams, as well as their efficacy, safety and cosmetic acceptability. Blood samples for pharmacogenetic analysis were collected from consenting participants in the clinical trial, to define a genetic basis for response to either treatment.

[0022] Among those genes selected for pharmacogenomic analysis were LTA, which codes for lymphotoxin alpha (LToα), and TNF, which codes for tumor necrosis factor alpha (TNF-α). The LTA and TNF genes are tandemly located in the gene-rich MHCIII region of 6p21.3 (see, FIG. 1). Both genes contain multiple polymorphisms, some of which have been well-characterized, as reviewed by Field M, Q J Med 94: 237-246 (2001). Both the LTA and the TNF gene products are cytokines involved in inflammatory processes. Both cytokines signal through TNF-α receptors, which are expressed in many different tissues, including the skin. Rulls SR & Sedgwick JD, Am J Hum Genet 65: 294-301 (1999). Furthermore, both LTA and TNF have been implicated in the pathogenesis of atopic disease. Polymorphisms in both these genes are associated with atopy, particularly asthma. Trabetti E et al., J Med Genet 36: 323-5 (1999); Izakovicova Holla L et al., Clin Exp Allergy 9: 1418-23 (2001); Castro J et al., J Investig Allergol Clin Immunol 3:149-5 (2000); Li Kam Wa TC et al., Clin Exp Allergy 29: 1204-8 (1999); and Zhu S et al. Am J Respir Crit Care Med 161: 1655 – 9 (2000). TNF-α has been extensively studied for its role in dermal inflammation. Both dermal mast cells and keratinocytes produce TNF-α. While expression of TNF-α is constitutive in the skin, the level of expression can be further induced by a variety of stimuli. TNF-α levels are elevated in skin lesions of psoriasis, and several reports have suggested that drugs that modulate TNF-α function are effective in the treatment of psoriasis, as reviewed by LaDuca JR & Gaspari AA, Dermatol Clin 19: 617-635 (2001) and

[0023] In the clinical trial and subsequent pharmacogenomics analysis, an association between pimecrolimus efficacy and the (-1031) TNF polymorphism was found in pediatric subjects (ages 2-17 years) with atopic dermatitis who were treated topically with the cream formulation of pimecrolimus. The polymorphism that associated with pimecrolimus efficacy is located -1031 from the transcription start site of the gene and changes the wild-type T to a C. The only subjects that experienced efficacy in this trial had a TT genotype at (-1031) TNF (SEQ ID NO:1). No patient with a C allele (CC (SEQ ID NO:2) or CT(SEQ ID NOS:1 and 2)) at that locus responded to pimecrolimus. This association did not hold for tacrolimus.

[0024] For a second SNP in the same chromosomal region, ASN60THR LTA, the data also suggested a trend toward significance.

[0025] These associations can reasonably be expected to hold for all age groups and for subjects with other inflammatory skin diseases. Moreover, the efficacy of pimecrolimus can reasonably be predicted when the compound is formulated as a tablet or aerosol. The method can be used for vertebrate subjects, particularly mammalian subjects and more particularly for human subjects.

[0026] Individuals carrying polymorphic alleles of interest (i.e., in genes from the TNF cluster, such as TNF and LTA) may be detected at the DNA, the RNA, or the protein level using a variety of techniques that are well known in the art. Strategies for identification and detection are described in e.g. EP 730,663, EP 717,113, and PCT US97/02102. The methods of the invention may involve the detection of pre-characterized polymorphisms, where the genotyping location and nature of polymorphic forms present at a site have already been determined (see, discussion above regarding LTA and TNF genes). The availability of this information allows sets of probes to be designed for specific identification of the known polymorphic forms. The identification of alleles containing single nucleotide polymorphisms may involve the amplification of DNA from target samples. This can be accomplished by e.g., PCR. See generally PCR Technology: Principles and Applications for DNA Amplification, (ed. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990). The detection of polymorphisms in specific DNA

Levels of TNF-α mRNA or protein can be determined by methods known to those of skill in the art. See, U.S. Pat. Nos. 6,566,501; 6,541,620; and 6,537,540. A discussion of the levels of the level of tumor necrosis factor in TNF-associated disorders is provided in U.S. Pat. No. 6,537,540 and references cited therein (all of which are incorporated by reference).

As used herein, the level of TNF-α mRNA (SEQ ID NO:7) in the sample is determined to be "high" when the ratio of TNF-α mRNA to β-actin expression (SEQ ID NO:9; see, Actor JK et al., Comb Chem High Throughput Screen 3(4):343-51 (August 2000)) or GAPDH expression (see, Anderson GD et al., J Clin Invest. 97(11):2672-9 (June 8
1, 1996)) in the sample is about twice as high or higher than the ratio of TNF-α mRNA to β-actin expression, as compared with a sample from an individual (or preferably a population of individuals) who does not have an inflammatory skin condition. As used herein, the level of TNF-a mRNA in the sample is determined to be “low or normal” when the ratio of TNF-α mRNA to β-actin expression in the sample is about equal to or less than the ratio of TNF-α mRNA to β-actin expression, as compared with a sample from an individual (or preferably, a population of individuals) who does not have an inflammatory skin condition. For guidance as to which TNF-α mRNA and protein levels tissue are generally expected to be “low”, “normal” or “high”, see, Van Deventer SJH, Gut 40: 443-8 (1997); McAlindon ME & Mahida YR, Aliment Pharmacol Ther 10(suppl 2): 72-4 (1996); Reimund J-M et al., J Clin Immunol 16: 144-50 (1996); Reinecker H-C et al., Clin Exp Immunol 94: 174-81 (1993); Murch SH et al., Gut. 34: 1705-9 (1993) and Grom AA et al., Arthritis Rheum 39: 1703-1710 (1996). Alternatively, one of skill in the art can define an average or expected level of TNF-α mRNA expression in a population, e.g., by performing the assay in ten or more control subjects (such as by methods shown in the EXAMPLE) and obtaining the average and standard deviation.

[0029] Samples for the determination of genetic polymorphisms, TNF mRNA levels (SEQ ID NO:7) or TNF protein levels (SEQ ID NO:8) can be collected from subjects by any appropriate method known to those of skill in the medical art. Samples can be fluid samples, such as from blood, mucus, lymphatic fluid, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid and semen or other bodily fluid. Alternatively, samples can be tissue samples, such as from biopsy samples, homogenate, lysate or extract prepared from a whole organism or a subset of its tissues, cells or component parts, or a fraction or portion thereof. A sample can also be a medium, such as a nutrient broth or gel in which an organism has been propagated, which contains cellular components, such as proteins or nucleic acid molecules.

[0031] Guidance for the use of tacrolimus ointment (0.03% or 0.1%) is provided by Fujisawa Healthcare Inc., Protopic® Prescribing Information, 45670 (December 2000). Guidance for the use of Prograf® (oral capsule or injectable) is provided by Fujisawa Healthcare Inc., Prograf® Prescribing Information, ZL40306 and Fujisawa Healthcare Inc., Prograf® Product Monograph. Additional guidance for the use of tacrolimus is provided by Ngheim P et al., J Am Acad Dermatol 46: 228-241 (2002) and references cited therein (all of which are incorporated by reference).

[0032] As used herein, a "high dose of pimecrolimus" is a dose substantially higher than the recommended dose of pimecrolimus. For example, for adults and children over two years of age, a thin layer of pimecrolimus cream 1% is applied to the affected area twice times a day, then rubbed in gently. A dose substantially higher than the recommended dose may be the application four times a day. Alternatively, a dose substantially higher than the recommended dose may be the application twice a day of a pimecrolimus formulation with a concentration of 2% or higher, if such be made available. Likewise, a "high dose of tacrolimus" is a dose substantially higher than the recommended dose of tacrolimus.

[0033] The use of other immunosuppressants, such as hydrocortisone, cyclosporine or sirolimus (rapamycin), in dermatology generally and in particular for atopic dermatitis, is well-known to those of skill in the medical arts. See, Marsland AM & Griffiths CE, Eur J Dermatol. 2(6):618-22 (November-December 2002) and Ngheim P et al., J Am Acad Dermatol 46: 228-241 (2002).


[0035] Single Nucleotide Polymorphisms. Sequence variation in the human genome consists primarily of single nucleotide polymorphisms ("SNPs") with the remainder of the sequence variations being short tandem repeats (including micro-satellites), long tandem repeats (mini-satellite) and other insertions and deletions. A SNP is a position at which two alternative bases occur at appreciable frequency (i.e. >1%) in the human population. A SNP is said to be "allelic" in that due to the existence of the polymorphism, some members of a species may have the unmutated sequence (i.e., the original "allele") whereas other members may have a mutated sequence (i.e., the variant or mutant allele). In the simplest case, only one mutated sequence may exist, and the polymorphism is said to be diallelic.
The occurrence of alternative mutations can give rise to triallelic polymorphisms, etc. SNPs are widespread throughout the genome and SNPs that alter the function of a gene may be direct contributors to phenotypic variation. Due to their prevalence and widespread nature, SNPs have potential to be important tools for locating genes that are involved in human disease conditions, see e.g., Wang et al., Science 280: 1077-1082 (1998), which discloses a pilot study in which 2,227 SNPs were mapped over a 2.3 megabase region of DNA.

[0036] An association between a single nucleotide polymorphisms and a particular phenotype does not indicate or require that the SNP is causative of the phenotype. Instead, such an association may indicate only that the SNP is located near the site on the genome where the determining factors for the phenotype exist and therefore is more likely to be found in association with these determining factors and thus with the phenotype of interest. Thus, a SNP may be in linkage disequilibrium (LD) with the 'true' functional variant. LD, also known as allelic association exists when alleles at two distinct locations of the genome are more highly associated than expected.

[0037] Thus a SNP may serve as a marker that has value by virtue of its proximity to a mutation that causes a particular phenotype.

[0038] SNPs that are associated with disease may also have a direct effect on the function of the gene in which they are located. A sequence variant may result in an amino acid change or may alter exon-intron splicing, thereby directly modifying the relevant protein, or it may exist in a regulatory region, altering the cycle of expression or the stability of the mRNA, see Nowotny P Current Opinions in Neurobiology 11:637-641 (2001).

[0039] It is increasingly clear that the risk of developing many common disorders and the metabolism of medications used to treat these conditions are substantially influenced by underlying genomic variations, although the effects of any one variant might be small.

[0040] Therefore, an association between a SNP and a clinical phenotype suggests, (1) the SNP is functionally responsible for the phenotype or, (2) there are other mutations near the location of the SNP on the genome that cause the phenotype. The 2nd possibility is based on the biology of inheritance. Large pieces of DNA are inherited and markers in close proximity to each other may not have been recombined in individuals that are unrelated for many generations, i.e., the markers are in linkage disequilibrium (LD).

[0041] Identification and characterization of SNPs. Many different techniques can be used to identify and characterize SNPs, including single-strand conformation
polymorphism analysis, heteroduplex analysis by denaturing high-performance liquid chromatography (DHPLC), direct DNA sequencing and computational methods, see Shi MM, Clin Chem 47:164-172 (2001). Thanks to the wealth of sequence information in public databases, computational tools can be used to identify SNPs in silico by aligning independently submitted sequences for a given gene (either cDNA or genomic sequences). Comparison of SNPs obtained experimentally and by in silico methods showed that 55% of candidate SNPs found by SNPFinder(http://ipgws.nci.nih.gov:82/perl/snp/snp_cgi.pl) have also been discovered experimentally, see, Cox et al. Hum Mutat 17:141-150 (2001). However, these in silico methods could only find 27% of true SNPs.

[0042] The most common SNP typing methods currently include hybridization, primer extension and cleavage methods. Each of these methods must be connected to an appropriate detection system. Detection technologies include fluorescent polarization, (see Chan X et al. Genome Res 9:492-499 (1999)), luminometric detection of pyrophosphate release (pyrosequencing), (see Ahmadian A et al., Anal Biochem 280:103-10 (2000)), fluorescence resonance energy transfer (FRET)-based cleavage assays, DHPLC, and mass spectrometry, (see Shi MM, Clin Chem 47:164-172 (2001) and U.S. Pat. No. 6,300,076 B1). Other methods of detecting and characterizing SNPs are those disclosed in U.S. Patents No. 6,297,018 B1 and 6,300,063 B1. The disclosures of the above references are incorporated herein by reference in their entirety.

[0043] In a particularly preferred embodiment the detection of the polymorphism can be accomplished by means of so called INVADER™ technology (available from Third Wave Technologies Inc. Madison, Wis.). In this assay, a specific upstream "invader" oligonucleotide and a partially overlapping downstream probe together form a specific structure when bound to complementary DNA template. This structure is recognized and cut at a specific site by the Cleavase enzyme, and this results in the release of the 5' flap of the probe oligonucleotide. This fragment then serves as the "invader" oligonucleotide with respect to synthetic secondary targets and secondary fluorescently labeled signal probes contained in the reaction mixture. This results in specific cleavage of the secondary signal probes by the Cleavase enzyme. Fluorescence signal is generated when this secondary probe, labeled with dye molecules capable of fluorescence resonance energy transfer, is cleaved. Cleavases have stringent requirements relative to the structure formed by the overlapping DNA sequences or flaps and can, therefore, be used to specifically detect single base pair mismatches immediately upstream of the cleavage site on the downstream

[0044] In some embodiments, a composition contains two or more differently labeled genotyping oligonucleotides for simultaneously probing the identity of nucleotides at two or more polymorphic sites. It is also contemplated that primer compositions may contain two or more sets of allele-specific primer pairs to allow simultaneous targeting and amplification of two or more regions containing a polymorphic site.

[0045] Genotyping oligonucleotides of the invention may also be immobilized on or synthesized on a solid surface such as a microchip, bead or glass slide (see, e.g., WO 98/20020 and WO 98/20019). Such immobilized genotyping oligonucleotides may be used in a variety of polymorphism detection assays, including but not limited to probe hybridization and polymerase extension assays. Immobilized genotyping oligonucleotides of the invention may comprise an ordered array of oligonucleotides designed to rapidly screen a DNA sample for polymorphisms in multiple genes at the same time.

[0046] An allele-specific oligonucleotide primer of the invention has a 3' terminal nucleotide, or preferably a 3' penultimate nucleotide, that is complementary to only one nucleotide of a particular SNP, thereby acting as a primer for polymerase-mediated extension only if the allele containing that nucleotide is present. Allele-specific oligonucleotide primers hybridizing to either the coding or noncoding strand are contemplated by the invention. An ASO primer for detecting gene polymorphisms could be developed using techniques known to those of skill in the art.

[0047] Other genotyping oligonucleotides of the invention hybridize to a target region located one to several nucleotides downstream of one of the novel polymorphic sites identified herein. Such oligonucleotides are useful in polymerase-mediated primer extension methods for detecting one of the novel polymorphisms described herein and therefore such genotyping oligonucleotides are referred to herein as “primer-extension oligonucleotides”. In a preferred embodiment, the 3'-terminus of a primer-extension oligonucleotide is a deoxynucleotide complementary to the nucleotide located immediately adjacent to the polymorphic site.

[0048] In another embodiment, the invention provides a kit comprising at least two genotyping oligonucleotides packaged in separate containers. The kit may also contain other components such as hybridization buffer (where the oligonucleotides are to be used as
a probe) packaged in a separate container. Alternatively, where the oligonucleotides are to be used to amplify a target region, the kit may contain, packaged in separate containers, a polymerase and a reaction buffer optimized for primer extension mediated by the polymerase, such as PCR.

[0049] The above described oligonucleotide compositions and kits are useful in methods for genotyping and/or haplotyping the gene in an individual. As used herein, the terms "genotype" and "haplotype" mean the genotype or haplotype containing the nucleotide pair or nucleotide, respectively, that is present at one or more of the novel polymorphic sites described herein and may optionally also include the nucleotide pair or nucleotide present at one or more additional polymorphic sites in the gene. The additional polymorphic sites may be currently known polymorphic sites or sites that are subsequently discovered.

[0050] One embodiment of the genotyping method involves isolating from the individual a nucleic acid mixture comprising the two copies of the gene, or a fragment thereof, that are present in the individual, and determining the identity of the nucleotide pair at one or more of the polymorphic sites in the two copies to assign a genotype to the individual. As will be readily understood by the skilled artisan, the two "copies" of a gene in an individual may be the same allele or may be different alleles. In a particularly preferred embodiment, the genotyping method comprises determining the identity of the nucleotide pair at each polymorphic site.

[0051] Typically, the nucleic acid mixture is isolated from a biological sample taken from the individual, such as a blood sample or tissue sample. Suitable tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal smears, skin and hair. The nucleic acid mixture may be comprised of genomic DNA, mRNA, or cDNA and, in the latter two cases, the biological sample must be obtained from an organ in which the gene is expressed. Furthermore it will be understood by the skilled artisan that mRNA or cDNA preparations would not be used to detect polymorphisms located in introns or in 5' and 3' nontranscribed regions. If a gene fragment is isolated, it must contain the polymorphic site(s) to be genotyped.

[0052] One embodiment of the haplotyping method comprises isolating from the individual a nucleic acid molecule containing only one of the two copies of the gene, or a fragment thereof, that is present in the individual and determining in that copy the identity of the nucleotide at one or more of the polymorphic sites in that copy to assign a haplotype.
to the individual. The nucleic acid may be isolated using any method capable of separating the two copies of the gene or fragment, including but not limited to, one of the methods described above for preparing isogenes, with targeted in vivo cloning being the preferred approach. As will be readily appreciated by those skilled in the art, any individual clone will only provide haplotype information on one of the two gene copies present in an individual. If haplotype information is desired for the individual's other copy, additional clones will need to be examined. Typically, at least five clones should be examined to have more than a 90% probability of haplotyping both copies of the gene in an individual. In a particularly preferred embodiment, the nucleotide at each of polymorphic site is identified.

[0053] In a preferred embodiment, a haplotype pair is determined for an individual by identifying the phased sequence of nucleotides at one or more of the polymorphic sites in each copy of the gene that is present in the individual. In a particularly preferred embodiment, the haplotyping method comprises identifying the phased sequence of nucleotides at each polymorphic site in each copy of the gene. When haplotyping both copies of the gene, the identifying step is preferably performed with each copy of the gene being placed in separate containers. However, it is also envisioned that if the two copies are labeled with different tags, or are otherwise separately distinguishable or identifiable, it could be possible in some cases to perform the method in the same container. For example, if first and second copies of the gene are labeled with different first and second fluorescent dyes, respectively, and an allele-specific oligonucleotide labeled with yet a third different fluorescent dye is used to assay the polymorphic site(s), then detecting a combination of the first and third dyes would identify the polymorphism in the first gene copy while detecting a combination of the second and third dyes would identify the polymorphism in the second gene copy.

[0054] In both the genotyping and haplotyping methods, the identity of a nucleotide (or nucleotide pair) at a polymorphic site(s) may be determined by amplifying a target region(s) containing the polymorphic site(s) directly from one or both copies of the gene, or fragment thereof, and the sequence of the amplified region(s) determined by conventional methods. It will be readily appreciated by the skilled artisan that only one nucleotide will be detected at a polymorphic site in individuals who are homozygous at that site, while two different nucleotides will be detected if the individual is heterozygous for that site. The polymorphism may be identified directly, known as positive-type identification, or by inference, referred to as negative-type identification. For example, where a SNP is known
to be guanine and cytosine in a reference population, a site may be positively determined to be either guanine or cytosine for all individual homozygous at that site, or both guanine and cytosine, if the individual is heterozygous at that site. Alternatively, the site may be negatively determined to be not guanine (and thus cytosine/cytosine) or not cytosine (and thus guanine/guanine).

[0055] In addition, the identity of the allele(s) present at any of the novel polymorphic sites described herein may be indirectly determined by genotyping a polymorphic site not disclosed herein that is in linkage disequilibrium with the polymorphic site that is of interest. Two sites are said to be in linkage disequilibrium if the presence of a particular variant at one site enhances the predictability of another variant at the second site (see, Stevens JC, *Mol Diag* 4:309-317 (1999)). Polymorphic sites in linkage disequilibrium with the presently disclosed polymorphic sites may be located in regions of the gene or in other genomic regions not examined herein. Genotyping of a polymorphic site in linkage disequilibrium with the novel polymorphic sites described herein may be performed by, but is not limited to, any of the above-mentioned methods for detecting the identity of the allele at a polymorphic site.

[0056] The target region(s) may be amplified using any oligonucleotide-directed amplification method, including but not limited to polymerase chain reaction (PCR) (U.S. Pat. No. 4,965,188), ligase chain reaction (LCR) (Barany *et al.*, *Proc Natl Acad Sci USA* 88:189-193 (1991); PCT patent application WO 90/01069), and oligonucleotide ligation assay (OLA) (Landegren *et al.*, *Science* 241:1077-1080 (1988)). Oligonucleotides useful as primers or probes in such methods should specifically hybridize to a region of the nucleic acid that contains or is adjacent to the polymorphic site. Typically, the oligonucleotides are between 10 and 35 nucleotides in length and preferably, between 15 and 30 nucleotides in length. Most preferably, the oligonucleotides are 20 to 25 nucleotides long. The exact length of the oligonucleotide will depend on many factors that are routinely considered and practiced by the skilled artisan.

[0057] Other known nucleic acid amplification procedures may be used to amplify the target region including transcription-based amplification systems (U.S. Pat. No. 5,130,238; EP 329,822; U.S. Pat. No. 5,169,766, WO 89/06700) and isothermal methods (Walker *et al.*, *Proc Natl Acad Sci USA* 89:392-396 (1992)).

[0058] A polymorphism in the target region may also be assayed before or after amplification using one of several hybridization-based methods known in the art. Typically,
allele-specific oligonucleotides are utilized in performing such methods. The allele-specific oligonucleotides may be used as differently labeled probe pairs, with one member of the pair showing a perfect match to one variant of a target sequence and the other member showing a perfect match to a different variant. In some embodiments, more than one polymorphic site may be detected at once using a set of allele-specific oligonucleotides or oligonucleotide pairs. Preferably, the members of the set have melting temperatures within 5°C and more preferably within 2°C, of each other when hybridizing to each of the polymorphic sites being detected.

[0059] Hybridization of an allele-specific oligonucleotide to a target polynucleotide may be performed with both entities in solution or such hybridization may be performed when either the oligonucleotide or the target polynucleotide is covalently or noncovalently affixed to a solid support. Attachment may be mediated, for example, by antibody-antigen interactions, poly-L-Lys, streptavidin or avidin-biotin, salt bridges, hydrophobic interactions, chemical linkages, UV cross-linking baking, etc. Allele-specific oligonucleotides may be synthesized directly on the solid support or attached to the solid support subsequent to synthesis. Solid-supports suitable for use in detection methods of the invention include substrates made of silicon, glass, plastic, paper and the like, which may be formed, for example, into wells (as in 96-well plates), slides, sheets, membranes, fibers, chips, dishes, and beads. The solid support may be treated, coated or derivatized to facilitate the immobilization of the allele-specific oligonucleotide or target nucleic acid.

[0060] The genotype or haplotype for the gene of an individual may also be determined by hybridization of a nucleic sample containing one or both copies of the gene to nucleic acid arrays and subarrays such as described in WO 95/11995. The arrays would contain a battery of allele-specific oligonucleotides representing each of the polymorphic sites to be included in the genotype or haplotype.

[0061] The identity of polymorphisms may also be determined using a mismatch detection technique, including but not limited to the RNase protection method using riboprobes (Winter et al., Proc Natl Acad Sci USA 82:7575 (1985); Meyers et al., Science 230:1242 (1985)) and proteins which recognize nucleotide mismatches, such as the E. coli mutS protein (Modrich P. Ann Rev Genet 25:229-253 (1991)). Alternatively, variant alleles can be identified by single strand conformation polymorphism (SSCP) analysis (Orita et al., Genomics 5:874-879 (1989); Humphries et al., in Molecular Diagnosis of Genetic Diseases, R. Elles, ed., pp. 321-340 (1996)) or denaturing gradient gel electrophoresis.
A polymerase-mediated primer extension method may also be used to identify the polymorphism(s). Several such methods have been described in the patent and scientific literature and include the "Genetic Bit Analysis" method (WO 92/15712) and the ligase / polymerase mediated genetic bit analysis (U.S. Pat. No. 5,679,524). Related methods are disclosed in WO 91/02087, WO 90/09455, WO 95/17676, U.S. Pat. Nos. 5,302,509 and 5,945,283. Extended primers containing a polymorphism may be detected by mass spectrometry as described in U.S. Pat. No. 5,605,798. Another primer extension method is allele-specific PCR (Ruafio et al., *Nucl Acids Res* 17:8392 (1989); Ruafio et al., *Nucl Acids Res* 19:6877-6882 (1991); WO 93/22456; Turki et al., *J Clin Invest* 95:1635-1641 (1995)). In addition, multiple polymorphic sites may be investigated by simultaneously amplifying multiple regions of the nucleic acid using sets of allele-specific primers as described in WO 89/10414.

In a preferred embodiment, the haplotype frequency data for each ethnogeographic group is examined to determine whether it is consistent with Hardy-Weinberg equilibrium. Hardy-Weinberg equilibrium (D.L. Hartl *et al.*, *Principles of Population Genomics, 3rd Ed.* (Sinauer Associates, Sunderland, MA, 1997) postulates that the frequency of finding the haplotype pair $H_1/H_2$ is equal to $P_{H,W}(H_1/H_2) = 2p(H_1) p(H_2)$ if $H_1 \neq H_2$ and $P_{H,W}(H_1/H_2) = p(H_1) p(H_2)$ if $H_1 = H_2$. A statistically significant difference between the observed and expected haplotype frequencies could be due to one or more factors including significant inbreeding in the population group, strong selective pressure on the gene, sampling bias, and/or errors in the genotyping process. If large deviations from Hardy-Weinberg equilibrium are observed in an ethnogeographic group, the number of individuals in that group can be increased to see if the deviation is due to a sampling bias. If a larger sample size does not reduce the difference between observed and expected haplotype pair frequencies, then one may wish to consider haplotyping the individual using a direct haplotyping method such as, for example, CLASPER System™ technology (U.S. Pat. No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin *et al.*, *Nucl Acids Res* 24:4841-4843 (1996)).

In one embodiment of this method for predicting a haplotype pair, the assigning step involves performing the following analysis. First, each of the possible haplotype pairs is compared to the haplotype pairs in the reference population. Generally, only one of the
haplotype pairs in the reference population matches a possible haplotype pair and that pair is assigned to the individual. Occasionally, only one haplotype represented in the reference haplotype pairs is consistent with a possible haplotype pair for an individual, and in such cases the individual is assigned a haplotype pair containing this known haplotype and a new haplotype derived by subtracting the known haplotype from the possible haplotype pair. In rare cases, either no haplotypes in the reference population are consistent with the possible haplotype pairs, or alternatively, multiple reference haplotype pairs are consistent with the possible haplotype pairs. In such cases, the individual is preferably haplotyped using a direct molecular haplotyping method such as, for example, CLASPER System™ technology (U.S. Pat. No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al., Nucl Acids Res 24:4841-4843 (1996)).

[0065] The invention also provides a method for determining the frequency of a genotype or haplotype in a population. The method comprises determining the genotype or the haplotype pair for the gene that is present in each member of the population, wherein the genotype or haplotype comprises the nucleotide pair or nucleotide detected at one or more of the polymorphic sites in the gene, and calculating the frequency any particular genotype or haplotype is found in the population. The population may be a reference population, a family population, a same sex population, a population group, a trait population (e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment).

[0066] In another aspect of the invention, frequency data for genotypes and/or haplotypes found in a reference population are used in a method for identifying an association between a trait and a genotype or a haplotype. The trait may be any detectable phenotype, including but not limited to susceptibility to a disease or response to a treatment. The method involves obtaining data on the frequency of the genotype(s) or haplotype(s) of interest in a reference population as well as in a population exhibiting the trait. Frequency data for one or both of the reference and trait populations may be obtained by genotyping or haplotyping each individual in the populations using one of the methods described above. The haplotypes for the trait population may be determined directly or, alternatively, by the predictive genotype to haplotype approach described above.

[0067] In another embodiment, the frequency data for the reference and/or trait populations is obtained by accessing previously determined frequency data, which may be in written or electronic form. For example, the frequency data may be present in a database
that is accessible by a computer. Once the frequency data is obtained, the frequencies of the genotype(s) or haplotype(s) of interest in the reference and trait populations are compared. In a preferred embodiment, the frequencies of all genotypes and/or haplotypes observed in the populations are compared. If a particular genotype or haplotype for the gene is more frequent in the trait population than in the reference population at a statistically significant amount, then the trait is predicted to be associated with that genotype or haplotype.

[0068] In a preferred embodiment statistical analysis is performed by the use of standard ANOVA tests with a Bonferoni correction and/or a bootstrapping method that simulates the genotype phenotype correlation many times and calculates a significance value. When many polymorphisms are being analyzed a correction to factor may be performed to correct for a significant association that might be found by chance. For statistical methods for use in the methods of this invention, see: Statistical Methods in Biology, 3rd edition, Bailey NTJ, (Cambridge Univ. Press, 1997); Introduction to Computational Biology, Waterman MS (CRC Press, 2000) and Bioinformatics, Baxevanis AD & Ouellette BFF editors (John Wiley & Sons, Inc., 2001).

[0069] In a preferred embodiment of the method, the trait of interest is a clinical response exhibited by a patient to some therapeutic treatment, for example, response to a drug targeting or response to a therapeutic treatment for a medical condition.

[0070] In another embodiment of the invention, a detectable genotype or haplotype that is in linkage disequilibrium with the genotype or haplotype of interest may be used as a surrogate marker. A genotype that is in linkage disequilibrium with a genotype may be discovered by determining if a particular genotype or haplotype for the gene is more frequent in the population that also demonstrates the potential surrogate marker genotype than in the reference population at a statistically significant amount, then the marker genotype is predicted to be associated with that genotype or haplotype and then can be used as a surrogate marker in place of the genotype.

[0071] Definitions. As used herein, “medical condition” includes but is not limited to any condition or disease manifested as one or more physical and/or psychological symptoms for which treatment is desirable, and includes previously and newly identified diseases and other disorders.

[0072] As used herein, the term “clinical response” means any or all of the following: a quantitative measure of the response, no response, and adverse response (i.e., side effects).
[0073] In order to deduce a correlation between clinical response to a treatment and a genotype or haplotype, data is obtained on the clinical responses exhibited by a population of individuals who received the treatment, hereinafter the "clinical population". This clinical data may be obtained by analyzing the results of a clinical trial that has already been run and/or the clinical data may be obtained by designing and carrying out one or more new clinical trials.

[0074] As used herein, the term "clinical trial" means any research study designed to collect clinical data on responses to a particular treatment, and includes but is not limited to phase I, phase II and phase III clinical trials. Standard methods are used to define the patient population and to enroll subjects.

[0075] It is preferred that the individuals included in the clinical population have been graded for the existence of the medical condition of interest. This grading of potential patients could employ a standard physical exam or one or more lab tests. Alternatively, grading of patients could use haplotyping for situations where there is a strong correlation between haplotype pair and disease susceptibility or severity.

[0076] The therapeutic treatment of interest is administered to each individual in the trial population and each individual’s response to the treatment is measured using one or more predetermined criteria. It is contemplated that in many cases, the trial population will exhibit a range of responses and that the investigator will choose the number of responder groups (e.g., low, medium, high) made up by the various responses. In addition, the gene for each individual in the trial population is genotyped and/or haplotyped, which may be done before or after administering the treatment.

[0077] After both the clinical and polymorphism data have been obtained, correlations between individual response and genotype or haplotype content are created. Correlations may be produced in several ways. In one method, individuals are grouped by their genotype or haplotype (or haplotype pair) (also referred to as a polymorphism group), and then the averages and standard deviations of clinical responses exhibited by the members of each polymorphism group are calculated.

[0078] These results are then analyzed to determine if any observed variation in clinical response between polymorphism groups is statistically significant. Statistical analysis methods which may be used are described in L.D. Fisher & G. vanBelle, *Biostatistics: A Methodology for the Health Sciences* (Wiley-Interscience, New York,
This analysis may also include a regression calculation of which polymorphic sites in the gene give the most significant contribution to the differences in phenotype.


Correlations may also be analyzed using analysis of variation (ANOVA) techniques to determine how much of the variation in the clinical data is explained by different subsets of the polymorphic sites in the gene. ANOVA is used to test hypotheses about whether a response variable is caused by or correlated with one or more traits or variables that can be measured (Fisher & vanBelle, supra, Ch. 10).

From the analyses described above, a mathematical model may be readily constructed by the skilled artisan that predicts clinical response as a function of genotype or haplotype content.

The identification of an association between a clinical response and a genotype or haplotype (or haplotype pair) for the gene may be the basis for designing a diagnostic method to determine those individuals who will or will not respond to the treatment, or alternatively, will respond at a lower level and thus may require more treatment, i.e., a greater dose of a drug. The diagnostic method may take one of several forms: for example, a direct DNA test (i.e., genotyping or haplotyping one or more of the polymorphic sites in the gene), a serological test, or a physical exam measurement. The only requirement is that there be a good correlation between the diagnostic test results and the underlying genotype or haplotype that is in turn correlated with the clinical response. In a preferred embodiment, this diagnostic method uses the predictive haplotyping method described above.

A computer may implement any or all analytical and mathematical operations involved in practicing the methods of the present invention. In addition, the computer may
execute a program that generates views (or screens) displayed on a display device and with which the user can interact to view and analyze large amounts of information relating to the gene and its genomic variation, including chromosome location, gene structure, and gene family, gene expression data, polymorphism data, genetic sequence data, and clinical data population data (e.g., data on ethnogeographic origin, clinical responses, genotypes, and haplotypes for one or more populations). The polymorphism data described herein may be stored as part of a relational database (e.g., an instance of an Oracle database or a set of ASCII flat files). These polymorphism data may be stored on the computer’s hard drive or may, for example, be stored on a CD-ROM or on one or more other storage devices accessible by the computer. For example, the data may be stored on one or more databases in communication with the computer via a network.

[0084] In other embodiments, the invention provides methods, compositions, and kits for haplotyping and/or genotyping the gene in an individual. The compositions contain oligonucleotide probes and primers designed to specifically hybridize to one or more target regions containing, or that are adjacent to, a polymorphic site. The methods and compositions for establishing the genotype or haplotype of an individual at the novel polymorphic sites described herein are useful for studying the effect of the polymorphisms in the etiology of diseases affected by the expression and function of the protein, studying the efficacy of drugs targeting, predicting individual susceptibility to diseases affected by the expression and function of the protein and predicting individual responsiveness to drugs targeting the gene product.

[0085] In yet another embodiment, the invention provides a method for identifying an association between a genotype or haplotype and a trait. In preferred embodiments, the trait is susceptibility to a disease, severity of a disease, the staging of a disease or response to a drug. Such methods have applicability in developing diagnostic tests and therapeutic treatments for all pharmacogenetic applications where there is the potential for an association between a genotype and a treatment outcome including efficacy measurements, PK measurements and side effect measurements.

[0086] The invention also provides a computer system for storing and displaying polymorphism data determined for the gene. The computer system comprises a computer processing unit; a display; and a database containing the polymorphism data. The polymorphism data includes the polymorphisms, the genotypes and the haplotypes identified for the gene in a reference population. In a preferred embodiment, the computer
system is capable of producing a display showing haplotypes organized according to their evolutionary relationships.

[0087] In another aspect, the invention provides SNP probes, which are useful in classifying people according to their types of genetic variation. The SNP probes according to the invention are oligonucleotides, which can discriminate between alleles of a SNP nucleic acid in conventional allelic discrimination assays.

[0088] As used herein, a “SNP nucleic acid” is a nucleic acid sequence, which comprises a nucleotide that is variable within an otherwise identical nucleotide sequence between individuals or groups of individuals, thus, existing as alleles. Such SNP nucleic acids are preferably from about 15 to about 500 nucleotides in length. The SNP nucleic acids may be part of a chromosome, or they may be an exact copy of a part of a chromosome, e.g., by amplification of such a part of a chromosome through PCR or through cloning. The SNP nucleic acids are referred to hereafter simply as “SNPs”. The SNP probes according to the invention are oligonucleotides that are complementary to a SNP nucleic acid.

[0089] As used herein, the term “complementary” means exactly complementary throughout the length of the oligonucleotide in the Watson and Crick sense of the word.

[0090] In certain preferred embodiments, the oligonucleotides according to this aspect of the invention are complementary to one allele of the SNP nucleic acid, but not to any other allele of the SNP nucleic acid. Oligonucleotides according to this embodiment of the invention can discriminate between alleles of the SNP nucleic acid in various ways. For example, under stringent hybridization conditions, an oligonucleotide of appropriate length will hybridize to one allele of the SNP nucleic acid, but not to any other allele of the SNP nucleic acid. The oligonucleotide may be labeled by a radiolabel or a fluorescent label. Alternatively, an oligonucleotide of appropriate length can be used as a primer for PCR, wherein the 3’ terminal nucleotide is complementary to one allele of the SNP nucleic acid, but not to any other allele. In this embodiment, the presence or absence of amplification by PCR determines the haplotype of the SNP nucleic acid.

[0091] Genomic and cDNA fragments of the invention comprise at least one novel polymorphic site identified herein and have a length of at least 10 nucleotides and may range up to the full length of the gene. Preferably, a fragment according to the present invention is between 100 and 3000 nucleotides in length, and more preferably between 200
and 2000 nucleotides in length, and most preferably between 500 and 1000 nucleotides in length.

[0092] In describing the polymorphic sites identified herein reference is made to the sense strand of the gene for convenience. However, as recognized by the skilled artisan, nucleic acid molecules containing the gene may be complementary double stranded molecules and thus reference to a particular site on the sense strand refers as well to the corresponding site on the complementary antisense strand. Thus, reference may be made to the same polymorphic site on either strand and an oligonucleotide may be designed to hybridize specifically to either strand at a target region containing the polymorphic site. Thus, the invention also includes single-stranded polynucleotides that are complementary to the sense strand of the genomic variants described herein.

[0093] In a preferred embodiment, such kit may further comprise a DNA sample collecting means.

[0094] In particular, the genotyping primer composition may comprise at least two sets of allele specific primer pairs. Preferably, the two genotyping oligonucleotides are packaged in separate containers.

[0095] It is to be understood that the methods of the invention described herein generally may further comprise the use of a kit according to the invention. Generally, the methods of the invention may be performed \textit{ex-vivo}, and such \textit{ex-vivo} methods are specifically contemplated by the present invention. Also, where a method of the invention may include steps that may be practiced on the human or animal body, methods that only comprise those steps which are not practiced on the human or animal body are specifically contemplated by the present invention.

[0096] Effect(s) of the polymorphisms identified herein on expression of may be investigated by preparing recombinant cells and/or organisms, preferably recombinant animals, containing a polymorphic variant of the gene. As used herein, "expression" includes but is not limited to one or more of the following: transcription of the gene into precursor mRNA; splicing and other processing of the precursor mRNA to produce mature mRNA; mRNA stability; translation of the mature mRNA into protein (including codon usage and tRNA availability); and glycosylation and/or other modifications of the translation product, if required for proper expression and function.

[0097] To prepare a recombinant cell of the invention, the desired isogene may be introduced into the cell in a vector such that the isogene remains extrachromosominal. In such
a situation, the gene will be expressed by the cell from the extrachromosomal location. In a preferred embodiment, the isogene is introduced into a cell in such a way that it recombines with the endogenous gene present in the cell. Such recombination requires the occurrence of a double recombination event, thereby resulting in the desired gene polymorphism. Vectors for the introduction of genes both for recombination and for extrachromosomal maintenance are known in the art, and any suitable vector or vector construct may be used in the invention. Methods such as electroporation, particle bombardment, calcium phosphate co-precipitation and viral transduction for introducing DNA into cells are known in the art; therefore, the choice of method may lie with the competence and preference of the skilled practitioner.

[0098] Recombinant organisms, i.e., transgenic animals, expressing a variant gene are prepared using standard procedures known in the art. Preferably, a construct comprising the variant gene is introduced into a nonhuman animal or an ancestor of the animal at an embryonic stage, i.e., the one-cell stage, or generally not later than about the eight-cell stage. Transgenic animals carrying the constructs of the invention can be made by several methods known to those having skill in the art. One method involves transfec ting into the embryo a retrovirus constructed to contain one or more insulator elements, a gene or genes of interest, and other components known to those skilled in the art to provide a complete shuttle vector harboring the insulated gene(s) as a transgene, see e.g., U.S. Pat. No. 5,610,053. Another method involves directly injecting a transgene into the embryo. A third method involves the use of embryonic stem cells.

[0099] Examples of animals, into which the isogenes may be introduced include, but are not limited to, mice, rats, other rodents, and nonhuman primates (see "The Introduction of Foreign Genes into Mice" and the cited references therein, In: Recombinant DNA, Eds. J. D. Watson, M. Gilman, J. Witkowski, & M. Zoller; W.H. Freeman and Company, New York, pages 254-272). Transgenic animals stably expressing a human isogene and producing human protein can be used as biological models for studying diseases related to abnormal expression and/or activity, and for screening and assaying various candidate drugs, compounds, and treatment regimens to reduce the symptoms or effects of these diseases.

[00100] In practicing the present invention, many conventional techniques in molecular biology, microbiology and recombinant DNA are used. These techniques are well-known and are explained in, e.g., "Current Protocols in Molecular Biology", Vols. I-III, Ausubel,
Ed. (1997); Sambrook et al., "Molecular Cloning: A Laboratory Manual", 2nd Ed., Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989); "DNA Cloning: A
Practical Approach", Vols. I and II, Glover, Ed. (1985); "Oligonucleotide Synthesis", Gait,
Ed. (1984); "Nucleic Acid Hybridization", Hames & Higgins, Eds. (1985); "Transcription
(1986); "Immobilized Cells and Enzymes", IRL Press (1986); Perbal, "A Practical Guide to
Molecular Cloning"; the series, Methods in Enzymol., Academic Press, Inc. (1984); "Gene
Transfer Vectors for Mammalian Cells", Miller and Calos, Eds., Cold Spring Harbor
Laboratory, NY (1987); and Methods in Enzymology, Vols. 154 and 155, Wu & Grossman,
and Wu, Eds., respectively.

[00101] The standard control levels of the gene expression product, thus determined in
the different control groups, would then be compared with the measured level of an gene
expression product in a given patient. This gene expression product could be the
characteristic mRNA associated with that particular genotype group or the polypeptide gene
expression product of that genotype group. The patient could then be classified or assigned
to a particular genotype group based on how similar the measured levels were compared to
the control levels for a given group.

[00102] As one of skill in the art will understand, there will be a certain degree of
uncertainty involved in making this determination. Therefore, the standard deviations of the
control group levels would be used to make a probabilistic determination and the methods
of this invention would be applicable over a wide range of probability based genotype
group determinations. Thus, for example and not by way of limitation, in one embodiment,
if the measured level of the gene expression product falls within 2.5 standard deviations of
the mean of any of the control groups, then that individual may be assigned to that genotype
group. In another embodiment if the measured level of the gene expression product falls
within 2.0 standard deviations of the mean of any of the control groups then that individual
may be assigned to that genotype group. In still another embodiment, if the measured level
of the gene expression product falls within 1.5 standard deviations of the mean of any of the
control groups then that individual may be assigned to that genotype group. In yet another
embodiment, if the measured level of the gene expression product is 1.0 or less standard
deviations of the mean of any of the control groups levels then that individual may be
assigned to that genotype group.
[00103] Thus this process will allow the determining, with various degrees of probability, which group a specific patient should be place in and such assignment to a genotype group would then determine the risk category into which the individual should be placed.

[00104] Methods to detect and measure mRNA levels and levels of polypeptide gene expression products are well known in the art and include the use of nucleotide microarrays and polypeptide detection methods involving mass spectrometers and/or antibody detection and quantification techniques. See also, Human Molecular Genetics, 2nd Edition. Tom Strachan & Andrew, Read (John Wiley and Sons, Inc. Publication, NY, 1999).

[00105] Furthermore, detection of the concentration of the polypeptide (protein) expression product of the gene in body fluids or tissues can be used to determine the presence or absence of the polymorphism, and the relative level of the polypeptide expression product can be used to determine if the polymorphism is present in a homozygous or heterozygous state and therefore the risk category of the individual.

[00106] As used herein, "medical condition" includes, but is not limited to, any condition or disease manifested as one or more physical and/or psychological symptoms for which treatment is desirable, and includes previously and newly-identified diseases and other disorders.

[00107] As used herein the term “polymorphism” shall mean any sequence variant present at a frequency of >1% in a population. The sequence variant may be present at a frequency significantly greater than 1% such as 5% or 10 % or more. Also, the term may be used to refer to the sequence variation observed in an individual at a polymorphic site. Polymorphisms include nucleotide substitutions, insertions, deletions and microsatellites and may, but need not, result in detectable differences in gene expression or protein function.

[00108] As used herein, the term "clinical response" means any or all of the following: a quantitative measure of the response, no response and adverse response, i.e., side effects.

[00109] As used herein the term “allele” shall mean a particular form of a gene or DNA sequence at a specific chromosomal location (locus).

[00110] As used herein, the term “genotype” shall mean an unphased 5’ to 3’ sequence of nucleotide pair(s) found at one or more polymorphic sites in a locus on a pair of homologous chromosomes in an individual. As used herein, genotype includes a full-genotype and/or a sub-genotype.
As used herein, the term "polynucleotide" shall mean any RNA or DNA, which may be unmodified or modified RNA or DNA. Polynucleotides include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

As used herein the term "gene" shall mean a segment of DNA that contains all the information for the regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression.

As used herein the term "polypeptide" shall mean any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. Polypeptide refers to both short chains, commonly referred to as peptides, glycopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.

As used herein, the term "polymorphic site" shall mean a position within a locus at which at least two alternative sequences are found in a population, the most frequent of which has a frequency of no more than 99%.

As used herein, the term "nucleotide pair" shall mean the nucleotides found at a polymorphic site on the two copies of a chromosome from an individual.

As used herein, the term "phased" means, when applied to a sequence of nucleotide pairs for two or more polymorphic sites in a locus, the combination of nucleotides present at those polymorphic sites on a single copy of the locus is known.

In order to deduce a correlation between clinical response to a treatment and a genotype or haplotype, it is necessary to obtain data on the clinical responses exhibited by a population of individuals who received the treatment, hereinafter the "clinical population".
This clinical data may be obtained by analyzing the results of a clinical trial that has already been run and/or the clinical data may be obtained by designing and carrying out one or more new clinical trials.

[00118] As used herein, the term "clinical trial" means any research study designed to collect clinical data on responses to a particular treatment, and includes, but is not limited to, Phase I, II and III clinical trials. Standard methods are used to define the patient population and to enroll subjects.

[00119] As used herein the term "locus" shall mean a location on a chromosome or DNA molecule corresponding to a gene or a physical or phenotypic feature.

[00120] The therapeutic treatment of interest is administered to each individual in the trial population and each individual's response to the treatment is measured using one or more predetermined criteria. It is contemplated that in many cases, the trial population will exhibit a range of responses and that the investigator will choose the number of responder groups, e.g., low, medium and high, made up by the various responses. In addition, the gene for each individual in the trial population is genotyped and/or haplotyped, which may be done before or after administering the treatment.

[00121] The Detection of Nucleic Acids and Proteins as Markers. In a particular embodiment, the level of mRNA corresponding to the marker can be determined both by in situ and by in vitro formats in a biological sample using methods known in the art. The term "biological sample" is intended to include tissues, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject. Many expression detection methods use isolated RNA. For in vitro methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from cells. See, e.g., Ausubel et al., Ed., Curr. Prot. Mol. Biol., John Wiley & Sons, NY (1987-1999). Additionally, large numbers of tissue samples can readily be processed using techniques well-known to those of skill in the art, such as, e.g., the single-step RNA isolation process of U.S. Pat. No. 4,843,155.

[00122] The isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, PCR analyses and probe arrays. One preferred diagnostic method for the detection of mRNA levels involve contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe can be, e.g., a full-length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100,
250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention. Other suitable probes for use in the diagnostic assays of the invention are described herein. Hybridization of an mRNA with the probe indicates that the marker in question is being expressed.

[00123] In one format, the mRNA is immobilized on a solid surface and contacted with a probe, for example, by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the markers of the present invention.

[00124] An alternative method for determining the level of mRNA corresponding to a marker of the present invention in a sample involves the process of nucleic acid amplification, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, U.S. Pat. No. 4,683,202 (1987); ligase chain reaction, Barany (1991), supra; self-sustained sequence replication, Guatelli et al., Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 1874-1878 (1990); transcriptional amplification system, Kwoh et al., Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 1173-1177 (1989); Q-Beta Replicase, Lizardi et al., Biol. Technology, Vol. 6, p. 1197 (1988); rolling circle replication, U.S. Pat. No. 5,854,033 (1988); or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well-known to those of skill in the art. These detection schemes are especially useful for the detection of the nucleic acid molecules if such molecules are present in very low numbers. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10-30 nucleotides in length and flank a region from about 50-200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

[00125] For in situ methods, mRNA does not need to be isolated from the cells prior to detection. In such methods, a cell or tissue sample is prepared/processed using known
histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.

[00126] As an alternative to making determinations based on the absolute expression level of the marker, determinations may be based on the normalized expression level of the marker. Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a gene that is not a marker, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes, such as the actin gene or epithelial cell-specific genes. This normalization allows the comparison of the expression level in one sample, e.g., a patient sample, to another sample or between samples from different sources.

[00127] Alternatively, the expression level can be provided as a relative expression level. To determine a relative expression level of a marker, the level of expression of the marker is determined for 10 or more samples of normal versus disease biological samples, preferably 50 or more samples, prior to the determination of the expression level for the sample in question. The mean expression level of each of the genes assayed in the larger number of samples is determined and this is used as a baseline expression level for the marker. The expression level of the marker determined for the test sample (absolute level of expression) is then divided by the mean expression value obtained for that marker. This provides a relative expression level.

[00128] Preferably, the samples used in the baseline determination will be from patients who do not have the polymorphism. The choice of the cell source is dependent on the use of the relative expression level. Using expression found in normal tissues as a mean expression score aids in validating whether the marker assayed is specific (versus normal cells). In addition, as more data is accumulated, the mean expression value can be revised, providing improved relative expression values based on accumulated data.

[00129] Detection of Polypeptides. In another embodiment of the present invention, a polypeptide corresponding to a marker is detected. A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide corresponding to a marker of the invention, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof, e.g., Fab or F(ab')₂ can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct-labeling of the probe or antibody by coupling, i.e., physically linking, a detectable substance to the probe or antibody, as well as
indirect-labeling of the probe or antibody by reactivity with another reagent that is directly-labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin.

[00130] Proteins from individuals can be isolated using techniques that are well-known to those of skill in the art. The protein isolation methods employed can, e.g., be such as those described in Harlow & Lane (1988), supra.

[00131] A variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody. Examples of such formats include, but are not limited to, EIA; radioimmunoassay (RIA), Western blot analysis and ELISA. A skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether cells express a marker of the present invention and the relative concentration of that specific polypeptide expression product in blood or other body tissues.

[00132] In one format, antibodies or antibody fragments, can be used in methods, such as Western blots or immunofluorescence techniques to detect the expressed proteins. In such uses, it is generally preferable to immobilize either the antibody or proteins on a solid support. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros and magnetite.

[00133] One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present invention. For example, protein isolated from patient cells can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support, such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the detectably-labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means and this measurement translated into a level or concentration of protein in blood or another body tissue.

[00134] The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample, e.g., any body fluid including, but not limited to, serum, plasma, lymph, cystic fluid, urine, stool, csf, acitic fluid or blood and including biopsy samples of body tissue. For example, the kit can
comprise a labeled compound or agent capable of detecting a polypeptide or an mRNA encoding a polypeptide corresponding to a marker of the invention in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample, e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide. Kits can also include instructions for interpreting the results obtained using the kit.

[00135] For antibody-based kits, the kit can comprise, e.g., 1) a first antibody, e.g., attached to a solid support, which binds to a polypeptide corresponding to a marker of the invention; and, optionally; and optionally 2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable label.

[00136] For oligonucleotide-based kits, the kit can comprise, e.g., 1) an oligonucleotide, e.g., a detectably-labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide corresponding to a marker of the invention; or 2) a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker of the invention.

[00137] The kit can also comprise, e.g., a buffering agent, a preservative or a protein-stabilizing agent. The kit can further comprise components necessary for detecting the detectable-label, e.g., an enzyme or a substrate. The kit can also contain a control sample or a series of control samples, which can be assayed and compared to the test sample. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

[00138] Kits. The kits of the invention may contain a written product on or in the kit container. The written product describes how to use the reagents contained in the kit to predict whether a patient will respond effectively to macrolactam treatment, especially pimecrolimus treatment. In several embodiments, the use of the reagents can be according to the methods of the invention.
EXAMPLE
PHARMACOGENETIC ANALYSIS OF PATIENT RESPONSE TO THERAPY IN
CLINICAL TRIAL: POTENTIAL ASSOCIATION OF PIMECROLIMUS EFFICACY
WITH POLYMORPHISMS IN THE TNF GENE CLUSTER

[00139] Genotyping selected candidate genes. Forty-six patients, corresponding to 24
patients who received tacrolimus and 22 patients who received pimecrolimus, were
analyzed for possible associations between genetic markers and treatment efficacy.

[00140] Thirty-one unique polymorphic sites in a total of 22 genes were analyzed.
TABLE 1 lists the genotype frequencies for each SNP examined in the trial population that
consented to participation in the pharmacogenetic analysis. Each SNP is identified by three
pieces of information: (1) REF_ACC, or the Genbank accession number where genomic
sequence for the gene can be found, (2) Position, which refers to the position of the
nucleotide within the REF_ACC that was interrogated, and (3) TWT SNP#, which refers to
the number assigned by Third Wave Technologies to the assay that was designed to assess
the genotype at the position defined by items 1 and 2. Location refers to the site within the
gene that harbors the polymorphism, if known.
<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Gene Name</th>
<th>TWT SNP #</th>
<th>REF_ACC</th>
<th>Allele 1 Freq.</th>
<th>Allele 2 Freq.</th>
<th>Position</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE</td>
<td>Angiotensin I converting enzyme</td>
<td>103199</td>
<td>AF1178569</td>
<td>0.50(T)</td>
<td>0.50(C)</td>
<td>10514</td>
<td></td>
</tr>
<tr>
<td>ACE</td>
<td>Angiotensin I converting enzyme</td>
<td>103200</td>
<td>AF1178569</td>
<td>0.56(A)</td>
<td>0.44(G)</td>
<td>14521</td>
<td></td>
</tr>
<tr>
<td>CCR2</td>
<td>chemokine (C-C motif) receptor 2</td>
<td>103240</td>
<td>U80924 (SEQ ID NO:10)</td>
<td>1.00(A)</td>
<td>0.00(G)</td>
<td>4201</td>
<td>3' UTR</td>
</tr>
<tr>
<td>CCR2</td>
<td>chemokine (C-C motif) receptor 2</td>
<td>47987</td>
<td>U80924 (SEQ ID NO:10)</td>
<td>0.77(G)</td>
<td>0.23(A)</td>
<td>46295</td>
<td>Exon 1</td>
</tr>
<tr>
<td>CCR5+</td>
<td>chemokine (C-C motif) receptor 5</td>
<td>128004</td>
<td>U95626</td>
<td>1.00(T)</td>
<td>0.00(A)</td>
<td>61785</td>
<td>Exon 2</td>
</tr>
<tr>
<td>CCR5</td>
<td>chemokine (C-C motif) receptor 5</td>
<td>128005</td>
<td>U95626</td>
<td>0.60(A)</td>
<td>0.40(G)</td>
<td>62035</td>
<td>promoter</td>
</tr>
<tr>
<td>CTLA4</td>
<td>cytotoxic T-lymphocyte-associated protein 4</td>
<td>128016</td>
<td>M74363</td>
<td>0.56(A)</td>
<td>0.44(G)</td>
<td>1241</td>
<td>Exon 1</td>
</tr>
<tr>
<td>ICAM1*</td>
<td>intercellular adhesion molecule 1</td>
<td>128063</td>
<td>X59287</td>
<td>0.98(A)</td>
<td>0.02(T)</td>
<td>120</td>
<td>Exon 2</td>
</tr>
<tr>
<td>ICAM1*</td>
<td>intercellular adhesion molecule 1</td>
<td>128062</td>
<td>X59288</td>
<td>0.98(G)</td>
<td>0.02(T)</td>
<td>659</td>
<td>Exon 4</td>
</tr>
<tr>
<td>IFNG</td>
<td>Interferon gamma</td>
<td>229376</td>
<td>J00219</td>
<td>0.65(A)</td>
<td>0.35(G)</td>
<td>5644</td>
<td>promoter</td>
</tr>
<tr>
<td>IFNG1+</td>
<td>Interferon gamma receptor 1</td>
<td>229419</td>
<td>U19241</td>
<td>1.00(G)</td>
<td>0.00(A)</td>
<td>4020</td>
<td>Exon 1</td>
</tr>
<tr>
<td>IFNG2</td>
<td>Interferon gamma receptor 2</td>
<td>252011</td>
<td>AP000113</td>
<td>0.84(A)</td>
<td>0.16(G)</td>
<td>42786</td>
<td>Exon 2</td>
</tr>
<tr>
<td>IL10</td>
<td>Interleukin 10</td>
<td>229400</td>
<td>X78437</td>
<td>0.67(A)</td>
<td>0.33(G)</td>
<td>8210</td>
<td>5'UTR</td>
</tr>
<tr>
<td>IL3</td>
<td>Interleukin 3</td>
<td>251975</td>
<td>AF365976</td>
<td>0.61(C)</td>
<td>0.39(T)</td>
<td>1990</td>
<td>Exon 1</td>
</tr>
<tr>
<td>IL3+</td>
<td>Interleukin 3</td>
<td>229368</td>
<td>AF365976</td>
<td>1.00(T)</td>
<td>0.00(C)</td>
<td>3622</td>
<td></td>
</tr>
<tr>
<td>IL4R</td>
<td>Interleukin 4</td>
<td>229406</td>
<td>AF421857</td>
<td>0.52(C)</td>
<td>0.48(T)</td>
<td>13715</td>
<td>Intron 5</td>
</tr>
<tr>
<td>IL5*</td>
<td>Interleukin 5</td>
<td>229372</td>
<td>AF353265</td>
<td>0.98(G)</td>
<td>0.02(A)</td>
<td>2718</td>
<td></td>
</tr>
<tr>
<td>IL8</td>
<td>Interleukin 8</td>
<td>229405</td>
<td>AF385628</td>
<td>0.55(C)</td>
<td>0.45(T)</td>
<td>4501</td>
<td>Intron 2</td>
</tr>
<tr>
<td>ITGB2+</td>
<td>Integrin, beta 2 (LFA1)</td>
<td>128081</td>
<td>X64075</td>
<td>1.00(G)</td>
<td>0.00(A)</td>
<td>64</td>
<td>Exon 5</td>
</tr>
<tr>
<td>LTA</td>
<td>Lymphotoxin alpha</td>
<td>229383</td>
<td>M55913 (SEQ ID NO:11)</td>
<td>0.59(C)</td>
<td>0.41(A)</td>
<td>800</td>
<td>Exon 3</td>
</tr>
<tr>
<td>LTB*</td>
<td>Lymphotoxin beta</td>
<td>128095</td>
<td>L11016 (SEQ ID NO:12)</td>
<td>0.91(C)</td>
<td>0.09(A)</td>
<td>5452</td>
<td></td>
</tr>
</tbody>
</table>
### TABLE 1 (Continued)

List of polymorphisms examined in the pharmacogenomic analysis

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Gene Name</th>
<th>TWT SNP #</th>
<th>REF ACC</th>
<th>Allele 1 Freq.</th>
<th>Allele 2 Freq.</th>
<th>Position</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>MICA</td>
<td>MHC class I polypeptide-related sequence A</td>
<td>229390</td>
<td>AF336081</td>
<td>0.98(A)</td>
<td>0.02(G)</td>
<td>106</td>
<td>Exon 2</td>
</tr>
<tr>
<td>MICA</td>
<td>MHC class I polypeptide-related sequence A</td>
<td>251974</td>
<td>AF336081</td>
<td>0.78(A)</td>
<td>0.22(G)</td>
<td>1612</td>
<td>Exon 5</td>
</tr>
<tr>
<td>MICA</td>
<td>MHC class I polypeptide-related sequence A</td>
<td>229395</td>
<td>AF336081</td>
<td>0.76(G)</td>
<td>0.24(A)</td>
<td>658</td>
<td>Exon 3</td>
</tr>
<tr>
<td>NFATC2</td>
<td>nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2</td>
<td>252013</td>
<td>AL035682</td>
<td>0.49(A)</td>
<td>0.51(G)</td>
<td>58458</td>
<td></td>
</tr>
<tr>
<td>PLGC1</td>
<td>Phospholipase C γ-1</td>
<td>229389</td>
<td>AL022394</td>
<td>0.69(C)</td>
<td>0.31(T)</td>
<td>64001</td>
<td></td>
</tr>
<tr>
<td>TGFβ1</td>
<td>Transforming growth factor β-1</td>
<td>128146</td>
<td>X05839</td>
<td>0.73(C)</td>
<td>0.27(T)</td>
<td>629</td>
<td>promoter</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor α</td>
<td>128152</td>
<td>M16441 (SEQ ID NO:7)</td>
<td>0.79(T)</td>
<td>0.21(C)</td>
<td>3064</td>
<td>promoter</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor α</td>
<td>128150</td>
<td>M16441 (SEQ ID NO:7)</td>
<td>0.85(C)</td>
<td>0.15(T)</td>
<td>3238</td>
<td>promoter</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor α</td>
<td>128148</td>
<td>M16441 (SEQ ID NO:7)</td>
<td>0.80(G)</td>
<td>0.20(A)</td>
<td>3787</td>
<td>promoter</td>
</tr>
<tr>
<td>TNFSF6</td>
<td>tumor necrosis factor receptor superfamily, member 6</td>
<td>128153</td>
<td>X81335</td>
<td>0.58(G)</td>
<td>0.42(A)</td>
<td>1110</td>
<td>promoter</td>
</tr>
</tbody>
</table>

+ This SNP is not polymorphic in this patient population.
* This population is not in Hardy Weinberg equilibrium for this SNP.

[00141] The *FKBPIA* gene (SEQ ID NO:13), which codes for FK506 Binding Protein 1A (macrophilin-12), the target of pimecrolimus and tacrolimus (FK506), was not genotyped, because the gene was found to contain no SNPs. No polymorphic sites in *FKBPIA* have been reported in public databases. We sequenced the *FKBPIA* gene to look for unknown SNPs, but found none.

[00142] To interrogate the genotype at each locus of interest, probe sets flanking the SNP were designed using publicly available databases such as OMIM, the SNP Consortium, LocusLink and dbSNP. The probe sets were synthesized by Third Wave Technologies, Inc. (TWT, Madison WI). Genotyping was performed with 60 ng of genomic

[00143] Genotyping of ASN60THR LTA. To confirm the results of the Third Wave Technologies genotyping assay for ASN60THR LTA (TWT #229383), a nested polymerase chain reaction (PCR) approach was used. All oligonucleotides were purchased from Research Genetics (Huntsville, AL). First, a 481 bp fragment was amplified using primers with the following sequences: forward (5’-acaccaacctgaagtcttc-3’; SEQ ID NO:14) reverse (5’-tctcaatccctgaggagttg-3’; SEQ ID NO:15). See Genbank accession number M55913 for the complete LTA sequence (SEQ ID NO:11). The amplicon was purified using Microcon 100 columns (Amlicon, Beverly, MA) and used as a template to amplify a 163 bp fragment using primers with the following sequences: forward (5’-tcagccccatctgacccctag-3’; SEQ ID NO:16) and reverse (5’-atgctccaatcaggtcgcaggttcccgg-3’; SEQ ID NO:17). Both PCR reactions were carried out in a Perkin Elmer 9700 thermocycler using 80 ng of genomic DNA, 60 ng of each primer, 1.0 Unit (U) of AmpliTaq polymerase (Perkin Elmer), and 200 μM dNTP (Pharmacia, Piscataway, N.J.) in a buffer consisting of 50 mM KCl, 10mM TRIS-HCl (pH 8.3), 1.5 mM MgCl and 0.01% gelatin. The PCR cycles for both amplifications consisted of the following: 94°C, 5 min; 94°C, 30 sec, 57°C, 30 sec, and 72°C, 30 sec for 35 cycles; 72°C, 10 minutes, then 4°C. The 163 bp amplicon was digested with Fau I (New England Biolabs, Beverly MA), and electrophoresed on a 4% agarose gel. A G allele produced an uncut 163 bp fragment, while an A produced 35 and 128 bp fragments. Both the 128 and 163 bp fragments were seen in heterozygote individuals. All but two of the genotypes determined by Third Wave Technologies technology could be confirmed by restriction digest.

[00144] Genotyping of (-1031) TNF. To confirm the results of the genotyping assay for TNF -1031, a 1113 bp fragment of the TNF promoter was PCR amplified and sequenced for each sample. PCR primers had the following sequences: forward (5’-TGGGAGTGAGAACTTCCCCAG-3’; SEQ ID NO:18) and reverse (5’-TGAGCTCATCTGGAGGAAGC-3’; SEQ ID NO:19). See Genbank accession number M16441 for the complete sequence of human TNF. PCR reactions were carried out using the same conditions described above. PCR products were purified through Microcon 100 (Amlicon, Beverly, MA) columns.
[00145] Following purification of the amplicon, 5 ng per 100 bp were used for sequencing with the ABI Prism Dye Terminator Cycle Sequencing kit as recommended (Perkin Elmer, Foster City, CA). Sequencing reactions contained either forward (5'-TGGAAGTGAAGCTTCCGAG-3'; SEQ ID NO:20) or reverse (5'-CTTAACCGTCCCTGATTC-3'; SEQ ID NO:21) primer and were run as follows: 96°C, 5 min; 96°C, 10 sec, 50°C, 5 sec, and 60°C, 4 min for 25 cycles; then 4°C. Sequencing reactions were purified with Centrisep spin columns (Princeton Separation, Adelphia, NJ) and run on the ABI 373A sequencer. DNA sequences were analyzed using ABI Prism Sequence Analysis V3.3 software.

[00146] Statistical analysis. Investigator global assessment (IGA) scores were used as the primary marker of efficacy in the pharmacogenetic studies. IGA scores at the end of the Investigator Blinded phase of the trial (Day 43) were used as the main time-point for comparison. Last observation carried forward imputations were only required for one subject at day 43. In this case, there was no IGA score available after Day 29, and the score on this day was used in place of a day 43 IGA score. IGA scores were re-coded, as was done to assess efficacy in the trial itself. An IGA score of 0 or 1 was considered successful treatment and IGA scores of 2-5 were counted as treatment failure. The severity of pruritus was also used as a marker of efficacy. Pruritus scores were dichotomized into absence (score = 0) or presence (score = 1, 2 or 3) of pruritus. The fisher's exact model was employed to examine the genotype effect on each efficacy variable. All statistical analyses were done using SAS version 8.2 software.

[00147] To correct for multiple testing, the Bonferroni correction method was applied to all results. The equation used to correct significance scores (p values) is: Bonferroni = P \times \eta, where P = p value for association between genotype and efficacy of treatment and \eta = number of polymorphic markers genotyped in the trial.

[00148] Demographics trial participants. As demonstrated in TABLE 2, the trial subjects that consented to the pharmacogenomics (PG) analysis were representative of the patient population in the trial overall in terms of gender, age, ethnicity, and response to treatment.
TABLE 2
Demographics of pharmacogenomic analysis participants compared to trial subjects

<table>
<thead>
<tr>
<th></th>
<th>Trial†</th>
<th>Pharmacogenomics Samples*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>tacrolimus</td>
<td>pimecrolimus</td>
</tr>
<tr>
<td>Age (years)</td>
<td>7.8</td>
<td>8.1</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>31 (41%)</td>
<td>45 (63%)</td>
</tr>
<tr>
<td>Black</td>
<td>14 (20%)</td>
<td>13 (18%)</td>
</tr>
<tr>
<td>Oriental</td>
<td>4 (6%)</td>
<td>3 (4%)</td>
</tr>
<tr>
<td>Other</td>
<td>21 (30%)</td>
<td>10 (14%)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>male</td>
<td>31 (44%)</td>
<td>31 (44%)</td>
</tr>
<tr>
<td>female</td>
<td>39 (56%)</td>
<td>40 (56%)</td>
</tr>
<tr>
<td>IGA (baseline)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3: 69</td>
<td>3: 70</td>
<td>3: 24</td>
</tr>
<tr>
<td>2: 1</td>
<td>2: 1</td>
<td></td>
</tr>
<tr>
<td>Efficacy (IGA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27 (40%)</td>
<td>22 (32%)</td>
<td>13 (52%)</td>
</tr>
<tr>
<td>Pruritus (day 1)</td>
<td>0: 1 (1%)</td>
<td>0: 2 (3%)</td>
</tr>
<tr>
<td>1: 13 (19%)</td>
<td>1: 14 (20%)</td>
<td>1: 6 (24%)</td>
</tr>
<tr>
<td>2: 33 (47%)</td>
<td>2: 25 (35%)</td>
<td>2: 11 (44%)</td>
</tr>
<tr>
<td>3: 23 (33%)</td>
<td>3: 30 (42%)</td>
<td>3: 8 (31%)</td>
</tr>
<tr>
<td>Pruritus (day 43)</td>
<td>0: 11 (16%)</td>
<td>0: 9 (13%)</td>
</tr>
<tr>
<td>1: 35 (50%)</td>
<td>1: 35 (49%)</td>
<td>1: 10 (40%)</td>
</tr>
<tr>
<td>2: 19 (27%)</td>
<td>2: 15 (21%)</td>
<td>2: 7 (28%)</td>
</tr>
<tr>
<td>3: 3 (4%)</td>
<td>3: 10 (14%)</td>
<td>3: 3 (12%)</td>
</tr>
</tbody>
</table>

† There were 70 subjects in the tacrolimus arm of the trial and 71 subjects in the pimecrolimus arm of the trial

* 24 subjects that took tacrolimus and 22 patients that took pimecrolimus were analyzed in the pharmacogenomic analysis.

$ IGA scores were taken at screening.

# Number and (percent) of patients that experienced efficacy, defined as an IGA score of 0 or 1 recorded on day 43 of treatment (end of blinded portion of the trial).

[00149] Association between (−1031) TNF and macrolactam efficacy. As stated above, the primary efficacy variable used in statistical analysis of each genetic marker was a re-coded IGA score. A total of 31 loci in 22 genes were genotyped. Of the 31 loci that were genotyped, 5 were not polymorphic in the pharmacogenomic analysis population and were dropped from the analysis. See, TABLE 1, above. Thus, the penalty for multiple testing in this analysis is 26.

[00150] When the trial was analyzed as a whole (both arms combined), 1 of the 26 SNPs analyzed showed a statistically significant association with efficacy. Tumor necrosis factor alpha, TNF, is located in the gene-rich MHC cluster on 6p21.3 (see, FIG. 1), and many of the genes in this region play important roles in inflammatory processes. The promoter of TNF is highly polymorphic. A SNP located −1031 bp from the transcription
start site of the gene associated with efficacy (p=0.04, see TABLE 3, below). These data demonstrate that patients that harbor a C allele (either CC homozygotes or CT heterozygotes) at (-1031) TNF were less likely to respond to treatment (4/17; 24% success rate) than were TT patients (17/29; 59% success rate).

TABLE 3
Association between (-1031) TNF and macrolactam efficacy

<table>
<thead>
<tr>
<th>Response to treatment</th>
<th>(-1031) TNF Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC</td>
</tr>
<tr>
<td>No Success (IGA ≥ 2)</td>
<td>2 (67%)</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>1 (33%)</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
</tr>
</tbody>
</table>

[00151] TABLE 3 demonstrates the number of subjects with each genotype that did or did not respond to treatment (referred to as “success” or “no success”, respectively), as determined by IGA scores on day 43 of treatment. Each square contains the number of individuals with the given genotype that fit the response category, followed by the percent. P value for the association is 0.04 (Fisher’s Exact).

[00152] We next examined the association between (-1031) TNF and efficacy for tacrolimus and pimecrolimus treatment independently. As seen in TABLE 4, those subjects who responded to pimecrolimus can be segregated from non-responders based on (-1031) TNF. Only subjects with a TT genotype (SEQ ID NO:1) at (-1031) TNF responded to pimecrolimus treatment. None of the ten subjects with a C allele (SEQ ID. NO:2; CC or CT) responded to pimecrolimus treatment. While response rate among CC and CT patients was 0%, 67% of the TTs experienced remission of their atopic dermatitis after taking pimecrolimus.

TABLE 4
Association between (-1031) TNF and pimecrolimus efficacy

<table>
<thead>
<tr>
<th>Response to pimecrolimus</th>
<th>(-1031) TNF Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC</td>
</tr>
<tr>
<td>No success (IGA ≥ 2)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Total</td>
<td>1</td>
</tr>
</tbody>
</table>

[00153] TABLE 4 demonstrates the number of pimecrolimus treated subjects with each genotype that did or did not respond to treatment (referred to as “success” or “no success”, respectively), as determined by IGA scores on day 43 of treatment. Each square contains
the number of individuals with the given genotype that fit the response category, followed by the percent. P value for the association is 0.003 (Fisher’s Exact).

[00154] However, genotype at this locus does not appear to influence tacrolimus efficacy. See, TABLE 5, below. Indeed, of the subjects that used tacrolimus, responders appear to be just as likely to be TT as CT or CC. Thus, the association seen between efficacy in the trial as a whole and (-1031) TNF holds only for pimecrolimus and not macrolactams in general.

<table>
<thead>
<tr>
<th>Response to tacrolimus</th>
<th>(-1031) TNF Genotype</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC</td>
<td>CT</td>
</tr>
<tr>
<td>No success (IGA ≥ 2)</td>
<td>1 (50%)</td>
<td>2 (40%)</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>1 (50%)</td>
<td>3 (60%)</td>
</tr>
<tr>
<td>Total</td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>

[00155] TABLE 5 demonstrates the number of tacrolimus treated subjects with each genotype that did or did not respond to treatment (referred to as “success” or “no success”, respectively), as determined by IGA scores on day 43 of treatment. Each square contains the number of individuals with the given genotype that fit the response category, followed by the percent. There was no association found between (-1031) TNF genotype response to tacrolimus; the P value for the association is 1.0 (Fisher’s Exact).

[00156] Association between ASN60THR LTA and macrolactam efficacy. When both arms of the trial were analyzed together, an association with efficacy was only found with (-1031) TNF. Interestingly, the data for a second polymorphism suggested a trend toward significance. A C→A polymorphism in exon 3 of LTA (SEQ ID NO:3), which results in the production of threonine instead of asparagine at the 60th amino acid of the protein (ASN60THR), was associated with efficacy in the clinical trial (p=0.07, see TABLE 6, below). LTA is tandemly located with TNF on 6p21.3, and numerous reports suggest that markers in TNF and LTA are in strong linkage disequilibrium. Bouma G et al., Scand J Immunol 43: 456-63 (1996); Noguchi E et al., Am J Respir Crit Care Med 166: 43-6 (2002); Moffatt M & Cookson W. Hum Molec Genet 6: 551-4 (1997); Messer G et al., J Exp Med 173: 209-19 (1991). Genotypes at this locus were determined in the pharmacogenomic analysis participants using an Invader Assay (TWT#229383) and confirmed by restriction digest. The data demonstrate that patients harboring an A, the wild-type allele(SEQ ID NO:3), at this locus were more likely to respond to treatment; the
response rate among subjects with an A allele (SEQ ID NO:4); AA or AC) was 57% 
(17/30), while the only 25% (4/16) of those subjects with a CC genotype experienced 
efficacy in the trial.

**TABLE 6**

Association between ASN60THR LTA and macrolactam efficacy (both arms combined)

<table>
<thead>
<tr>
<th>Response to Treatment</th>
<th>ASN60THR LTA Genotype</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA</td>
<td>AC</td>
<td>CC</td>
<td></td>
<td>Total</td>
</tr>
<tr>
<td>No Success (IGA ≥ 2)</td>
<td>3 (30%)</td>
<td>10 (50%)</td>
<td>12 (75%)</td>
<td></td>
<td>25</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>7 (70%)</td>
<td>10 (50%)</td>
<td>4 (25%)</td>
<td></td>
<td>21</td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
<td>20</td>
<td>16</td>
<td></td>
<td>46</td>
</tr>
</tbody>
</table>

[00157]  TABLE 6 demonstrates the number of subjects in the clinical trial with each 
genotype that did or did not respond to treatment (referred to as “success” or “no success”, 
respectively), as determined by IGA scores on day 43 of treatment. Each square contains 
the number of individuals with the given genotype that fit the response category, followed 
by the percent. While a significant association was not found (P value = 0.07, Fisher’s 
Exact), the P value approaches significance and is suggestive of a possible association.

[00158]  We next examined the association between ASN60THR LTA and each arm of 
the clinical trial independently. As anticipated, a significant association was found for 
pimecrolimus (P=0.02, see TABLE 7, below), and a dosage effect was seen with the 
polymorphism. Patients with a CC genotype at this locus responded poorly to pimecrolimus 
(1/8 or 11% were successfully treated). However, patients with an AC genotype responded 
better (4/10 or 40% response rate), and all patients with an AA genotype responded to the 
treatment (3/3).

**TABLE 7**

Association between ASN60THR LTA and pimecrolimus efficacy

<table>
<thead>
<tr>
<th>Response to pimecrolimus</th>
<th>ASN60THR LTA Genotype</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA</td>
<td>AC</td>
<td>CC</td>
<td></td>
<td>Total</td>
</tr>
<tr>
<td>No success (IGA ≥ 2)</td>
<td>0 (0%)</td>
<td>6 (60%)</td>
<td>8 (89%)</td>
<td></td>
<td>13</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>3 (100%)</td>
<td>4 (40%)</td>
<td>1 (11%)</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>10</td>
<td>9</td>
<td></td>
<td>22</td>
</tr>
</tbody>
</table>

[00159]  TABLE 7 demonstrates the number of pimecrolimus treated subjects with each 
genotype that did or did not respond to treatment (referred to as “success” or “no success”, 
respectively), as determined by IGA scores on day 43 of treatment. Each square contains 
the number of individuals with the given genotype that fit the response category, followed 
by the percent. The P value for the association is 0.02 (Fisher’s Exact).
A similar relationship was not found between ASN60THR LTA and tacrolimus efficacy. As seen in TABLE 8, the presence of the A allele at ASN60THR LTA had no influence on response to tacrolimus. As was found with (-1031) TNF, the association between ASN60THR LTA and efficacy in the clinical trial is driven by the pimecrolimus arm of the trial.

**TABLE 8**

Association between ASN60THR LTA and tacrolimus efficacy

<table>
<thead>
<tr>
<th>Response to tacrolimus</th>
<th>ASN60THR LTA Genotype</th>
<th>AA</th>
<th>AC</th>
<th>CC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No success (IGA ≥ 2)</td>
<td></td>
<td>3 (43%)</td>
<td>4 (40%)</td>
<td>4 (57%)</td>
<td>11</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td></td>
<td>4 (57%)</td>
<td>6 (60%)</td>
<td>3 (42%)</td>
<td>13</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>7</td>
<td>10</td>
<td>7</td>
<td>24</td>
</tr>
</tbody>
</table>

TABLE 8 demonstrates the number of tacrolimus treated subjects with each genotype that did or did not respond to treatment (referred to as “success” or “no success”, respectively), as determined by IGA scores on day 43 of treatment. Each square contains the number of individuals with the given genotype that fit the response category, followed by the percent. There was no association found between ASN60THR LTA genotype and response to tacrolimus; the P value for the association is 1.0 (Fisher’s Exact).

**Association between polymorphic markers and relief from pruritus.** A secondary efficacy variable used in the trial was pruritus. An analysis was done to see if ASN60THR LTA and (-1031) TNF associated with this efficacy variable (assessed on day 43). Results of the analysis for ASN60THR LTA and (-1031) TNF are shown in TABLES 9 and 10, respectively.

Few subjects (7/46) in the pharmacogenomics group experienced relief from itching. Findings for the primary efficacy variable (IGA) suggested that the presence of a C allele at ASN60THR LTA decreased the likelihood of response to treatment. While a statistically significant association between ASN60THR LTA and pruritus was not found, no subject that was homozygous CC at this locus experienced relief from itching as a result of treatment in this trial. For (-1031) TNF; while analysis of the primary efficacy variable IGA suggested that TT subjects were far more likely to respond to treatment, the same cannot be said when pruritus scores are analyzed for the trial as a whole. The two arms of the trial could not be separated for analysis of pruritus because the number of responders is too small. Only two pimecrolimus subjects in the pharmacogenomic analysis samples
experienced relief from itching. However, both of the pimecrolimus subjects that experienced efficacy with respect to pruritus were TT at (-1031) TNF.

**TABLE 9**
Association between **ASN60THR LTA** and pruritus (both arms combined).

<table>
<thead>
<tr>
<th>Response to treatment</th>
<th>ASN60THR LTA Genotype</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA (x%)</td>
<td>AC (x%)</td>
</tr>
<tr>
<td>No Success (Pru=1,2,3)</td>
<td>7 (70%)</td>
<td>16 (80%)</td>
</tr>
<tr>
<td>Success (Pru=0)</td>
<td>3 (30%)</td>
<td>4 (20%)</td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
<td>16</td>
</tr>
</tbody>
</table>

[00164] TABLE 9 demonstrates the number of subjects with each genotype at the ASN60THR LTA locus studied that did or did not respond to treatment, as determined by pruritus scores on day 43 of treatment. Treatment was considered successful if the patient reported no pruritus (score = 0). Each square contains the number of individuals with the given genotype that fit the response category, followed by the percent. A significant association was not found between ASN60THR LTA genotype and relief from pruritus (P=0.06, Fisher’s Exact), however the P value for the association approached significance.

**TABLE 10**
Association between (-1031) TNF and pruritus following treatment (both arms combined)

<table>
<thead>
<tr>
<th>Response to treatment</th>
<th>(-1031) TNF Genotype</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC (x%)</td>
<td>CT (x%)</td>
</tr>
<tr>
<td>No success (Pru=1,2,3)</td>
<td>3 (100%)</td>
<td>12 (86%)</td>
</tr>
<tr>
<td>Success (Pru=0)</td>
<td>0 (0%)</td>
<td>2 (14%)</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>14</td>
</tr>
</tbody>
</table>

[00165] TABLE 10 demonstrates the number of subjects with each genotype at (-1031) TNF that did or did not respond to treatment, as determined by pruritus scores on day 43 of treatment. Treatment was considered successful if the patient reported no pruritus (score = 0). Each square contains the number of individuals with the given genotype that fit the response category, followed by the percent. No association was found (P=1.0, Fisher’s Exact).

[00166] Genotypes at (-1031) TNF and ASN60THR LTA. Genotypes of anonymized patients at these two 6p21.3 loci were obtained. Only subjects with a TT genotype at (-1031) TNF responded to pimecrolimus therapy. The observation that individuals that are TT homozygotes for (-1031) TNF are either AA homozygotes, AC heterozygotes, or CC
homozygotes or for ASN60THR LTA show that (-1031) TNF and ASN60THR are not in complete linkage disequilibrium.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Allele 1</th>
<th>Allele 2</th>
<th>Surrounding Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTA</td>
<td>C</td>
<td>A</td>
<td>GTGAGCAGCAGGTTTGAGG[CA]TGCTGTGGGCAAGATGCATCTTGCGGGT (SEQ ID NOS: 3 and 4)</td>
</tr>
<tr>
<td>TNF</td>
<td>T</td>
<td>C</td>
<td>AGCAGAAGGAGCTGAGAAGAGTA[CA]GAAGGAAAATCGGGGCTGAGGGGGGCGGG (SEQ ID NOS: 1 and 2)</td>
</tr>
</tbody>
</table>

[00167] Associations between pimecrolimus and tacrolimus and other markers typed.
All of the other molecular markers typed were checked to see if they segregated responders from non-responders for each arm of the trial independently. No additional associations were found for pimecrolimus, though one association was found for tacrolimus. A G→A polymorphism in the coding region of CCR2 (SEQ ID NO:6; see TWT #47987), which results in a change in a valine to isoleucine (VAL64ILE), associated with response to treatment with tacrolimus (p=0.04, see TABLE 11, above). The P value for the association between pimecrolimus efficacy and VAL64ILE CCR2 was 1.0 (Fisher’s Exact).

[00168] CCR2 encodes chemokine (C-C) motif receptor 2, a receptor for monocyte chemoattractant protein-1 and a chemokine that mediates monocyte infiltration in inflammatory diseases. CCR2 encodes for both known isoforms of the receptor for monocyte chemoattractant protein-1 (MCP-1, also known as SCYA2), a chemokine which specifically mediates monocyte chemotaxis. MCP-1 has been shown to be involved with inflammatory diseases like rheumatoid arthritis and atherosclerosis. Boring L et al., Nature 394:894-7 (1998). The VAL64ILE polymorphism occurs in the first transmembrane region of CCR2 and has been studied in the context of HIV-1 infection and AIDS. Mummidi S et al., Nature Med 4: 786-93 (1998). The association found was p=0.04.

[00169] These data demonstrate that an A allele at VAL64ILE CCR2 were more likely to respond to tacrolimus treatment; 8/10 or 80% of AG subjects experienced efficacy, as compared to 4/13 or 31% of GG subjects. (There were no AA subjects in the population). This association is weaker than the associations seen with pimecrolimus efficacy, particularly for (-1031) TNF and pimecrolimus efficacy (p=0.003).
TABLE 12
Association between VAL63ILE CCR2 (TWT# 47987) and tacrolimus efficacy

<table>
<thead>
<tr>
<th>Response to tacrolimus</th>
<th>VAL63ILE CCR2 Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA</td>
</tr>
<tr>
<td>No success (IGA ≥ 2)</td>
<td>0</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
</tr>
</tbody>
</table>

[00170] TABLE 12 demonstrates the number of tacrolimus treated subjects with each genotype at VAL63ILE CCR2 that did or did not respond to treatment (determined by IGA scores on day 43 of treatment). Each square contains the number of individuals with the given genotype that fit the response category, followed by the percent. P value for the association was 0.04 (Fisher’s Exact).

[00171] LTB (SEQ ID NO 12; see TWT # 128095) is also located in the TNF gene cluster on 6p21.3. A polymorphism in LTB was also typed in this analysis (SEQ ID NO:22). As shown below, however, there is no association between TWT#128095 and efficacy in the clinical trial. No association was found when pimecrolimus and tacrolimus subjects were analyzed independently, either.

TABLE 13
Relationship between efficacy in trial (both arms combined) and LTB (TWT#128095); data demonstrate no association (p=1.0, Fisher’s Exact)

<table>
<thead>
<tr>
<th>Response to treatment</th>
<th>LTB (TWT#128095)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC</td>
</tr>
<tr>
<td>No success (IGA ≥ 2)</td>
<td>3 (50%)</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>3 (50%)</td>
</tr>
<tr>
<td>Total</td>
<td>16</td>
</tr>
</tbody>
</table>

TABLE 14
Relationship between efficacy in among pimecrolimus-treated subjects and LTB (TWT#128095); data demonstrate no association (p=1.0, Fisher’s Exact)

<table>
<thead>
<tr>
<th>Response to pimecrolimus</th>
<th>LTB (TWT#128095)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC</td>
</tr>
<tr>
<td>No success (IGA ≥ 2)</td>
<td>0 (50%)</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Total</td>
<td>1</td>
</tr>
</tbody>
</table>
TABLE 15
Relationship between efficacy in among tacrolimus-treated subjects and LTB (TWT#128095); data demonstrate no association (p=1.0, Fisher’s Exact)

<table>
<thead>
<tr>
<th>Response to tacrolimus</th>
<th>LTB (TWT#128095)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC</td>
<td>CC</td>
<td>Total</td>
</tr>
<tr>
<td>No success (IGA ≥ 2)</td>
<td>3 (60%)</td>
<td>8 (44%)</td>
<td>11</td>
</tr>
<tr>
<td>Success (IGA = 0 or 1)</td>
<td>2 (40%)</td>
<td>10 (56%)</td>
<td>12</td>
</tr>
<tr>
<td>Total</td>
<td>5</td>
<td>18</td>
<td>23</td>
</tr>
</tbody>
</table>

[00172] These data help to localize the genetic region that is responsible for response to pimecrolimus; the biologically relevant polymorphism does not appear to be localized proximal to TNF.

[00173] In summary, either LTA or TNF plays an important role in determining efficacy of pimecrolimus in the treatment of pediatric atopic dermatitis. By contrast, response to tacrolimus appears to be influenced by other biological pathways. Thus, different biological mechanisms influence response to pimecrolimus and tacrolimus. While pimecrolimus and tacrolimus have substantial structural similarities and both target macrophilin-12 with the ultimate effect of inhibiting calcineurin, the two compounds are known to have distinct properties. Nghiem P et al., J Am Acad Dermatol 46: 228-241 (2002) and references cited therein.

[00174] All references cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. In addition, all GenBank accession numbers, Unigene Cluster numbers and protein accession numbers cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each such number was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
[00175] The present invention is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the invention. Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatus within the scope of the invention, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications and variations are intended to fall within the scope of the appended claims. The present invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.
CLAIMS

We claim:

1. The use of pimecrolimus in the manufacture of a medicament for the treatment of inflammatory disease in a selected patient population, wherein the patient population is selected on the basis of the genotype of the patients at a genetic locus from the TNF gene cluster indicative of efficacy of pimecrolimus in treating inflammatory disease.

2. The use of tacrolimus in the manufacture of a medicament for the treatment of inflammatory disease in a selected patient population, wherein the patient population is selected on the basis of the genotype of the patients at the CCR2 genetic locus indicative of efficacy of tacrolimus in treating inflammatory disease.

3. A method for treating a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus or tacrolimus is indicated, comprising the steps of:
   (a) obtaining the genotype of a subject at a genetic locus from the TNF gene cluster indicative of efficacy of a selected macrolactam formulation in treating the condition;
   (b) administering either the selected macrolactam formulation or an alternative treatment for the condition to the subject.

4. The method of claim 3, wherein the selected macrolactam formulation comprises pimecrolimus.

5. The method of claim 3, wherein the selected macrolactam formulation comprises tacrolimus.

6. The method of any one of claims 3 to 5, wherein the genetic locus is the human TNF gene or a gene in a vertebrate species homologous to the human TNF gene.
7. The use of claim 1 or the method of any one of claims 3 to 6, wherein the genetic locus is the (-1031) TNF locus of the human TNF gene or a corresponding locus in a vertebrate species homologous to the human TNF gene.

8. The method of any one of claims 3, 4, 6 or 7, wherein the selected macro lactam formulation comprises pimecrolimus, when the (-1031) TNF genetic locus has a TT genotype.

9. The method of any one of claims 3 to 7, wherein the alternative treatment for the condition is selected from the group consisting of a high dose of pimecrolimus, pimecrolimus and an alternative immunosuppressant, and an alternative immunosuppressant, when the (-1031) TNF locus has a CC or CT genotype.

10. The method of claim 9, wherein the alternative immunosuppressant is selected from the group consisting of hydrocortisone, cyclosporine, tacrolimus and sirolimus.

11. The use of claim 1 or the method of claim 3, wherein the genetic locus is the human LTA gene or a gene in a vertebrate species homologous to the human LTA gene.

12. The use of claim 1 or 11 or the method of claim 3 or 11, wherein the genetic locus is the ASN60THR LTA locus of the human LTA gene or a corresponding locus in a vertebrate species homologous to the human LTA gene.

13. The method of any one of claims 3, 11 or 12, wherein the selected macro lactam formulation comprises pimecrolimus, when the ASN60THR LTA genetic locus has an AA or AC genotype.

14. The method of any one of claims 3, 11 or 12, wherein the alternative treatment for the condition is selected from the group consisting of a high dose of pimecrolimus, pimecrolimus and an alternative immunosuppressant, and an alternative immunosuppressant, when the ASN60THR LTA locus has a CC genotype.
15. The method of claim 14, wherein the alternative immunosuppressant is selected from the group consisting of hydrocortisone, cyclosporine, tacrolimus and sirolimus.

16. A method for treating a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus or tacrolimus is indicated, comprising the steps of:
(a) obtaining the genotype of a subject at a genetic locus indicative of efficacy of a selected macrolactam formulation in treating the condition, where the genetic locus is the human CCR2 gene or a gene in a vertebrate species homologous to the human CCR2 gene;
(b) administering either the selected macrolactam formulation or an alternative treatment for the condition to the subject.

17. The use of claim 2 or the method of claim 16, wherein the genetic locus is the VAL64ILE CCR2 locus of the human CCR2 gene or a corresponding locus in a vertebrate species homologous to the human CCR2 gene.

18. The method of claim 16 or 17, wherein the selected macrolactam formulation comprises tacrolimus, when the VAL64ILE CCR2 genetic locus has a GG genotype.

19. The method of claim 16 or 17, wherein the alternative treatment for the condition is selected from the group consisting of a high dose of tacrolimus, tacrolimus and an alternative immunosuppressant, and an alternative immunosuppressant, when the VAL64ILE CCR2 locus has an AG genotype.

20. The method of claim 16, 17 or 19, wherein the alternative immunosuppressant is selected from the group consisting of hydrocortisone, cyclosporine, pimecrolimus and sirolimus.
21. A method for treating a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus is indicated, comprising the steps of:

(a) obtaining a measurement of the level of TNF-α mRNA in a sample from a subject, where the sample is taken from non-inflamed tissue; and

(b) either:

(i) administering a pimecrolimus formulation to the subject when the level of TNF-α mRNA in the sample is low or normal; or

(ii) administering either (A) a pimecrolimus formulation in combination with another immunosuppressant or (B) another immunosuppressant to the subject when the level of TNF-α mRNA in the sample is elevated.

22. A method for treating a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus is indicated, comprising the steps of:

(a) obtaining a measurement of the level of TNF-α protein in a sample from a subject, where the sample is taken from non-inflamed tissue; and

(b) either:

(i) administering a pimecrolimus formulation to the subject when the level of TNF-α protein in the sample is low or normal; or

(ii) administering either (A) a pimecrolimus formulation in combination with another immunosuppressant or (B) another immunosuppressant to the subject when the level of TNF-α protein in the sample is elevated.
23. A method for determining a treatment strategy for a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus is indicated, said method comprises analyzing the level of TNF-\(\alpha\) mRNA or TNF-\(\alpha\) protein in a sample from the subject; and wherein the treatment strategy comprises the selection of a pimecrolimus formulation as treatment when the level of TNF-\(\alpha\) mRNA or TNF-\(\alpha\) protein in the sample is low or normal; or the selection of either (A) a pimecrolimus formulation in combination with another immunosuppressant or (B) another immunosuppressant as treatment when the level of TNF-\(\alpha\) mRNA or TNF-\(\alpha\) protein in the sample is elevated.

24. A method for choosing subjects for inclusion in a clinical trial for determining the efficacy of a pimecrolimus formulation, comprising the steps of:
   (a) interrogating the genotype of a subject at the (-1031) TNF polymorphism locus;
   (b) then:
      (i) including in the trial if they are TT at this locus;
      (ii) excluded if they are CC or CT at this locus; or
      (iii) both (i) and (ii).

25. A kit for use in determining a treatment strategy for a condition, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus or tacrolimus is indicated, comprising:
   (a) a reagent for detecting a biomarker of efficacy of treatment of the condition by a macrolactam formulation;
   (b) a container for the reagent; and
   (c) a written product on or in the container describing the use of the biomarker in determining a treatment strategy for the condition.

26. The kit of claim 25, wherein the biomarker is a genetic polymorphism in a gene selected from the group consisting of TNF, LTA and CCR2.
27. The kit of claim 25 or 26, wherein the reagent for detecting the biomarker is a set of primer pairs that hybridize to a polynucleotide on either the side of the genetic polymorphism in the gene selected from the group consisting of TNF, LTA and CCR2 and which define a nucleotide region that spans the genetic polymorphism.

28. The kit of claim 25, wherein the biomarker is the level of TNF-α mRNA in a sample from a subject to be treated.

29. The kit of claim 25, wherein the biomarker is the level of TNF-α protein in a sample from a subject to be treated.

30. A method for determining a treatment strategy for a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus or tacrolimus is indicated, said method comprises analyzing the genotype of a subject at a genetic locus from the TNF gene cluster indicative of efficacy of a selected macrolactam formulation in treating the condition.

31. The method of claim 30, wherein the genetic locus is the human TNF gene or a gene in a vertebrate species homologous to the human TNF gene.

32. The method of claim 30 or 31, wherein the genetic locus is the (-1031) TNF locus of the human TNF gene or a corresponding locus in a vertebrate species homologous to the human TNF gene.

33. The method of any one of claims 30 to 32, wherein the treatment strategy comprises the selection of a macrolactam formulation comprising pimecrolimus as treatment, when the (-1031) TNF genetic locus has a TT genotype.

34. The method of any one of claims 30 to 32, wherein the treatment strategy comprises the selection of a high dose of pimecrolimus, pimecrolimus and an alternative immunosuppressant, or an alternative immunosuppressant as treatment, when the (-1031) TNF locus has a CC or CT genotype.
35. The method of claim 34, wherein the alternative immunosuppressant is selected from the group consisting of hydrocortisone, cyclosporine, tacrolimus and sirolimus.

36. The method of claim 30, wherein the genetic locus is the human LTA gene or a gene in a vertebrate species homologous to the human LTA gene.

37. The method of claim 36, wherein the genetic locus is the ASN60THR LTA locus of the human LTA gene or a corresponding locus in a vertebrate species homologous to the human LTA gene.

38. The method of claim 36 or 37, wherein the treatment strategy comprises the selection of a macrolactam formulation comprising pimecrolimus as treatment, when the ASN60THR LTA genetic locus has an AA or AC genotype.

39. The method of claim 36 or 37, wherein the treatment strategy comprises the selection of a high dose of pimecrolimus, pimecrolimus and an alternative immunosuppressant, or an alternative immunosuppressant as treatment, when the ASN60THR LTA locus has a CC genotype.

40. The method of claim 39, wherein the alternative immunosuppressant is selected from the group consisting of hydrocortisone, cyclosporine, tacrolimus and sirolimus.
41. A method for determining a treatment strategy for a condition in a subject, wherein the condition is selected from the group consisting of atopic dermatitis, psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis or other condition for which pimecrolimus or tacrolimus is indicated, said method comprises analyzing the genotype of a subject at a genetic locus indicative of efficacy of a selected macrolactam formulation in treating the condition, where the genetic locus is the human CCR2 gene or a gene in a vertebrate species homologous to the human CCR2 gene.

42. The method of claim 41, wherein the genetic locus is the VAL64ILE CCR2 locus of the human CCR2 gene or a corresponding locus in a vertebrate species homologous to the human CCR2 gene.

43. The method of claim 41 or 42, wherein the treatment strategy comprises the selection of a macrolactam formulation comprising tacrolimus as treatment, when the VAL64ILE CCR2 genetic locus has a GG genotype.

44. The method of claim 41 or 42, comprising the selection of a high dose of tacrolimus, tacrolimus and an alternative immunosuppressant, or an alternative immunosuppressant as treatment, when the VAL64ILE CCR2 locus has an AG genotype.

45. The method of claim 44, wherein the alternative immunosuppressant is selected from the group consisting of hydrocortisone, cyclosporine, pimecrolimus and sirolimus.
Regions within the human MHC

<table>
<thead>
<tr>
<th>Ch6</th>
<th>Class</th>
<th>II</th>
<th>III</th>
<th>I</th>
<th>Ch6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HLA</td>
<td>DP</td>
<td>DQ</td>
<td>DR</td>
<td>C2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DQ</td>
<td>DR</td>
<td>C2</td>
<td>C4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HSP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TNF</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>B</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G</td>
</tr>
</tbody>
</table>

- LST1
- LTB
- TNF
- LTA

cen  -1031 *  ASN60THR  tel

FIG. 1
<110> Novartis AG
    McCullough, Karen
    Ide, Susan
    Lavedan, Christian
<120> USE OF GENETIC POLYMORPHISMS THAT
    ASSOCIATE WITH EFFICACY OF TREATMENT OF INFLAMMATORY DISEASE

<130> DV/4-33389A
<150> 60/508,971
<151> 2003-10-06
<160> 22
<170> FastSEQ for Windows Version 4.0
<210> 1
<211> 53
<212> DNA
<213> Homo sapiens

<220>
<221> variation
<222> (1)...(53)
<223> TNF locus variant (T at position -1031)

<221> variation
<222> (23)...(0)
<223> T
<400> 1
agcagaaggag aagctgagaa gatgaaggaa aagtcaggt ctggaggccc ggg 53
<210> 2
<211> 53
<212> DNA
<213> Homo sapiens

<220>
<221> variation
<222> (1)...(53)
<223> TNF locus variant (C at position -1031)

<221> variation
<222> (23)...(0)
<223> C
<400> 2
agcagaaggag aagctgagaa gcgaaggaa aagtcaggt ctggaggccc ggg 53
<210> 3
<211> 48
<212> DNA
<213> Homo sapiens

<220>
<221> variation
<222> (1)...(48)
<223> LTA locus variant (C)

<221> variation
<222> (20)...(0)
<223> C
<400> 3
gtgacgacga gtttggggc tgctgtgggc aagatgcatc ttggggtg 48

<210> 4
<211> 48
<212> DNA
<213> Homo sapiens

<220>
<221> variation
<222> (1)...(48)
<223> LTA locus variant (A; ASN60THR)

<221> variation
<222> (20)...(0)
<223> A

<400> 4
gtgacgacga gtttgggga tgctgtgggc aagatgcatc ttggggtg 48

<210> 5
<211> 50
<212> DNA
<213> Homo sapiens

<220>
<221> variation
<222> (1)...(50)
<223> CCR2 locus variant (G)

<221> variation
<222> (10)...(0)
<223> G

<400> 5
atgctgggtcg tcctcacttt aataaactgc aaaaaagctga agtgcttgac 50

<210> 6
<211> 50
<212> DNA
<213> Homo sapiens

<220>
<221> variation
<222> (1)...(50)
<223> CCR2 locus variant (A; VAL64ILE)

<221> variation
<222> (10)...(0)
<223> A

<400> 6
atgctgggctca tcctcacttt aataaactgc aaaaaagctga agtgcttgac 50

<210> 7
<211> 702
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)...(702)
<223> Tumor necrosis factor alpha (TNFalpha) mRNA coding region

<400> 7
atg agc act gaa agc atg atc cgg gac gtt gag ctg gcc gag gag gcg 48
SEQLIST.TXT
Leu Pro Lys Lys Thr Gly Gly Pro Gln Gly Ser Arg Arg Cys Leu Phe
20 25 30
Leu Ser Leu Phe Ser Phe Leu Ile Val Ala Gly Ala Thr Thr Leu Phe
35 40 45
Cys Leu Leu His Phe Gly Val Ile Gly Pro Gln Arg Glu Glu Phe Pro
50 55 60
Arg Asp Leu Ser Leu Ile Ser Pro Leu Ala Gln Ala Val Arg Ser Ser
65 70 75 80
Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
85 90 95
Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu
100 105 110
Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser
115 120 125
Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe Lys Gly Gln Gly
130 135 140
Cys Pro Ser Thr His Val Leu Thr His Thr Ser Arg Ile Ala
145 150 155 160
Val Ser Tyr Gln Thr Lys Val Leu Asn Leu Ser Ala Ile Lys Ser Pro
165 170 175
Cys Gln Arg Glu Thr Pro Glu Gly Ala Gln Ala Lys Pro Trp Tyr Gln
180 185 190
Pro Ile Tyr Leu Gly Val Phe Gln Leu Gln Lys Gly Asp Arg Leu
195 200 205
Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu Asp Phe Ala Glu Ser Gly
210 215 220
Gln Val Tyr Phe Gly Ile Ile Ala Leu
225 230

<210> 9
<211> 1793
<212> DNA
<213> Homo sapiens

<220> CDS
<221> (74)...(1201)
<223> beta-actin expression (ACTB) mRNA coding region

<400> 9
cgcctccgcc ccgagagcac agagcctgcg ctttgccgat ccgccgcccg tccacacccg 60
cgcctgcgcc acc atg gat gat gat gat gtc gtc gtc gtc gac aac 109
  Met Asp Asp Asp Ala Lea Leu Val Val Asp Asn
1  1

ggc tcc ggc atg tgt aag ggc gtc ggc ggc gag gat gcc ccc cgg 157
  Gly Ser Gly Met Cys Lys Ala Gly Phe Ala Gly Asp Asp Ala Pro Arg
15  20  25

gcc gtc ttc ccc tcc atc gtg ggg cgc ccc agg cac cag ggc gtc atg
30  35  40
  Ala Val Phe Pro Ser Ile Val Gly Arg Pro Arg His Gln Gly Val Met

gtg ggc atg tgt cag aag gat tcc tat gtg ggc gag gag ggc cag agc 205
45 50 55 60
  Val Gly Met Gly Glu Asp Ser Tyr Val Glu Asp Ala Glu Ser
aag aga ggc atc ctc acc ctg aag tac ccc atc gag cac gcc atc gtc 253
45 50 55 60
  Lys Arg Gly Ile Leu Thr Leu Lys Tyr Pro Ile Gln His Gly Ile Val
acc aac tgt gac gac atg gag aaa atc tgt cac ccc acc acc ttc tac aat 301
65 70 75
  Thr Asn Trp Met Glu Ile Thr Asp His His Thr Phe Tyr Asn

349

397

gag cttg gct ggt gct ccc gag gag cac ccc gttg ctt ctg acc gag gcc 397
  Glu Leu Arg Val Ala Pro Glu Glu His Pro Val Leu Thr Glu Ala

Page 4
SEQLIST.TXT

365 370 375

acttagttgc gtatcaccct ttcttgacaac aaccttaacct gcgcagaaaaa caagatgaga 1271
ttggcatggc ttatagttgtg tttttttttt tttttttttt ttttgcttg 1331
acttaggatt taaacactgg aacggtgaag gtgacagcag tcgggtgag cagatcact 1391
ccaaagttca caatggtgccc gaggaccttg atttggatattg tattggttcac 1451
tccaaatagctttcctacctg ataatagccttctt cccctggtattcattatc 1511
ttccctcaagttgagttg aagacggccct tcctctccat caagcccccagcagggaggt gatagcatttg 1571
ttacctcatatg tgcacatattagttgata cggaggttcgagttcagcacctta 1631
tttttttttt tttaatactt gcgttcttaata tttttttttttt tttttttttt 1691
tgagatgtgata gacccctcatg tccccccccttc tccccccccccct tccccccccccct 1751
gtacacgccg ttgagacacctg ttagaaaaa gtcgacaccc c ta 1793

<210> 10
<211> DNA
<212> Homo sapiens

<220>
<221> CDS
<222> (51)...(991)
<223> chemokine (C C motif) receptor 2 (CCR2) mRNA coding region

<400> 10
acagagaaag ttgattgacac aagagcgcat ttcccagaac atg ctc Met Leu

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>55</td>
<td>60</td>
<td>65</td>
</tr>
<tr>
<td>70</td>
<td>75</td>
<td>80</td>
</tr>
<tr>
<td>85</td>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>105</td>
<td>110</td>
<td>115</td>
</tr>
<tr>
<td>125</td>
<td>130</td>
<td>135</td>
</tr>
<tr>
<td>140</td>
<td>145</td>
<td>150</td>
</tr>
<tr>
<td>155</td>
<td>160</td>
<td>165</td>
</tr>
</tbody>
</table>

56
SEQLIST.TXT

<220> CDS
<221> Lymphotoxin alpha (LTA) mRNA coding region
<222> (I)...(618)
<223> 11
atg acc cca cca gaa cgt ctc ctc ctc cca agg gtg tgt ggc acc acc
Met Thr Pro Pro Glu Arg Leu Phe Leu Pro Arg Val Cys Gly Thr Thr
1 5 10 15

ctc cac ctc ctc ctc ggg ctc gtt ctc ctc ggg ggc
Leu His Leu Leu Leu Gly Leu Val Leu Pro Gly Ala
20 25 30

cag ggg ctc ctt gtt ggc ctc cca ctc tca gct gcc cag act gcc
Gln Gly Leu Pro Gly Val Gly Leu Thr Pro Ser Ala Ala Gln Thr Ala
35 40 45

192

cgt cac cac ccc aag atg cat ctt gcc cac aac acc ctc aac cca gct
Arg Gin His Pro Lys Met His Leu Ala His Ser Thr Leu Lys Pro Ala
50 55 60

gct cac ctc att gga gac ccc aac aac qac aac tca ctc tgg aca
Ala His Leu Ile Asp Pro Ser Lys Gin Asn Ser Leu Leu Trp Arg
65 70 75 80

gca aac acg gac cgt gcc ttc ctc cag gat ggt ttc ggc ttc tgc aag
Ala Asn Thr Asp Arg Ala Phe Leu Gln Gin Phe Ser Ala Ser Gin
85 90 95

aat tct ctc tgg gcc ccc acc aac aat ggc act tac ttc gtc tac gcc cag
Asn Ser Leu Leu Val Pro Thr Ser Gly Ile Tyr Phe Val Tyr Ser Gin
100 105 110

gtt gtc ttc tct ggg aac gcc tac tct ccc aag gcc acc ttc cca
Val Val Phe Ser Gly Lys Ala Tyr Ser Pro Lys Ala Thr Ser Ser Pro
115 120 125

cct tac ctc ggc cat gag gtt cag ctc ttc ctc ctc ctc cag tac ctc ctc
Leu Tyr Leu Ala His Glu Gin Leu Phe Ser Gin Tyr Pro Phe
130 135 140

cat gtt ctc ctc ctc aag ctc cag aag tat gtt tat cca ggg ctc cag
His Val Pro Leu Leu Ser Ser Gin Lys Met Val Tyr Pro Gly Leu Gin
145 150 155 160

528
gaa ccc tgt ctc cac tgg atg tac cac ggg gct gcc ttc cag ctc acc
Glu Pro Trp Leu His Ser Met Tyr His Gin Ala Ala Phe Leu Thr
165 170 175

cag gga gag ctc ttc gcc ccc acg ctc ctc ccc ctc cag ctc ctc
Gln Gin Asp Gin Leu Ser Thr His Thr Gin Ile Pro His Leu Val
180 185 190

cag cag ctt act gtt ttt gga gcc ttc gct ctc tag
Leu Ser Pro Ser Thr Val Phe Gin Ala Phe Ala Leu
195 200 205

618

<210> 12
<211> 894
<212> DNA
<213> Homo sapiens
<220> CDS
<221> Lymphotoxin alpha (LTA) mRNA coding region
<222> (I)...(743)
<table>
<thead>
<tr>
<th>Position</th>
<th>Amino Acid</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-10</td>
<td>Met Gly Ala Leu Gly Leu Glu Gly Arg Gly Gly Arg Leu Gln</td>
<td></td>
</tr>
<tr>
<td>11-15</td>
<td>Gly Arg Gly Ser Leu Leu Ala Val Ala Gly Ala Thr Ser Leu Val</td>
<td></td>
</tr>
<tr>
<td>16-20</td>
<td>Thr Leu Leu Leu Ala Val Pro Ile Thr Val Leu Ala Val Leu Ala Leu</td>
<td></td>
</tr>
<tr>
<td>21-25</td>
<td>Val Pro Gln Gly Leu Val Thr Glu Thr Ala Asp Pro Gly</td>
<td></td>
</tr>
<tr>
<td>26-30</td>
<td>Gln Ala Ala Gln Glu Leu Gly Leu Phe Gln Lys Leu Pro Glu</td>
<td></td>
</tr>
<tr>
<td>31-35</td>
<td>Ala Gln Cag Cag Caa Gga Ctg Ggg Ttt Cag Aag Ctg Cca Cag Gag Gag</td>
<td></td>
</tr>
<tr>
<td>36-40</td>
<td>Pro Gly Thr Asp Leu Ser Pro Gly Leu Pro Ala Ala His Leu Ile Gly</td>
<td></td>
</tr>
<tr>
<td>41-45</td>
<td>Ala Phe Thr Leu Ser Gly Leu Pro Ser Asp Ala Glu Gln</td>
<td></td>
</tr>
<tr>
<td>46-50</td>
<td>Pro Leu Gly Leu Lys Gly Gly Leu Val Trp Gly Thr Thr Lys Gly Gln</td>
<td></td>
</tr>
<tr>
<td>51-55</td>
<td>Ala Phe Thr Leu Ser Gly Leu Pro Ser Gln</td>
<td></td>
</tr>
<tr>
<td>56-60</td>
<td>Pro Leu Gln Asp Gly Tyr Tyr Leu Tyr Cys Leu Val Gly Tyr Arg</td>
<td></td>
</tr>
<tr>
<td>61-65</td>
<td>Gly Arg Ala Pro Pro Gly Gly Asp Pro Gln Gly Arg Ser Val Thr</td>
<td></td>
</tr>
<tr>
<td>66-70</td>
<td>Pro Leu Ser Leu Tyr Arg Ala Gly Gly Ala Tyr Gly Pro Gly Thr</td>
<td></td>
</tr>
<tr>
<td>71-75</td>
<td>Pro Glu Leu Leu Leu Leu Gly Arg Val Thr Pro Val Leu Asp</td>
<td></td>
</tr>
<tr>
<td>76-80</td>
<td>Pro Ala Arg Arg Glu Tyr Gly Pro Leu Trp Thr Tyr Ser Val Gly</td>
<td></td>
</tr>
<tr>
<td>81-85</td>
<td>Phe Gly Gly Leu Val Glu Leu Arg Arg Gly Glu Arg Val Tyr Val Asn</td>
<td></td>
</tr>
<tr>
<td>86-90</td>
<td>Atg Cag Ccc Gag Aag Caa Gg Tcc Gag Cag Ccc Ctg Ggg Tga Gg Gaaatagga Gtgcgttggc gcaggtgcgtg</td>
<td></td>
</tr>
<tr>
<td>91-95</td>
<td>Gly Ala Val Met Val Gly</td>
<td></td>
</tr>
<tr>
<td>96-100</td>
<td>Gcctgccgccgccagcc ccaggaccgg gagagaagtga gggggtgcgt tgggcaggtgcgtg</td>
<td></td>
</tr>
<tr>
<td>101-105</td>
<td>aatatggggg gcctgccgccgccagcc ccaggaccgg gagagaagtga gggggtgcgt tgggcaggtgcgtg</td>
<td></td>
</tr>
</tbody>
</table>
SEQLIST.TXT
tgaaatgga ttttgaacct gatgaaata aagaatggaa agcttcagtg ctgccgataaa 893
a 894

<210> 13
<211> 327
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)...(327)
<223> FKBP1A open reading frame for FK506 Binding Protein 1A (macrophilin 12) mRNA coding region

<400> 13
atg gga ctc gat gaa acc aca tcc cca gga cac ggg cgc acc ttc
Met Gly Val Glu Val Thr Ile Ser Pro Gly Asp Gly Arg Thr Phe 48
1 5 10 15
ccc aag cgc cag acc tgc gtt gtt cac tac acc ggg atg ctt gaa
Pro Lys Arg Gly Glu Thr Val His Tyr Thr Gly Met Leu Glu 96
20
pro lys arg gly glu thr val his tyr thr gly met leu glu 30
25

<400> 14
<210> 14
<211> 21
<212> DNA
<213> Homo sapiens

<220>
<221> primer_bind
<222> (1)...(21)
<223> Amplification primer for human LTA - forward

<400> 14
acaccacctg aacgcctcctt c 21

<400> 15
<210> 15
<211> 21
<212> DNA
<213> Homo sapiens

<220>
<221> primer_bind
<222> (1)...(21)
<223> Amplification primer for human LTA - reverse

<400> 15
ttcaatccg tgaggaagtg g

<210>  16
<211>  24
<212> DNA
<213> Homo sapiens

<220>
<221> primer_bind
<222> (1)...(24)
<223> Sequencing primer for human LTA - forward

<400>  16
tcagccaaac cttgagccct agag

<210>  17
<211>  34
<212> DNA
<213> Homo sapiens

<220>
<221> primer_bind
<222> (1)...(34)
<223> Sequencing primer for human LTA - reverse

<400>  17
atgttttacca atgaggtgag cagcaggttt gcgg

<210>  18
<211>  20
<212> DNA
<213> Homo sapiens

<220>
<221> primer_bind
<222> (1)...(20)
<223> Amplification primer for human TNF - forward

<400>  18
tgggagtgag aacctcccaag

<210>  19
<211>  20
<212> DNA
<213> Homo sapiens

<220>
<221> primer_bind
<222> (1)...(20)
<223> Amplification primer for human TNF - reverse

<400>  19
tgagctcatc tggaggaagc

<210>  20
<211>  20
<212> DNA
<213> Homo sapiens

<220>
<221> primer_bind
<222> (1)...(20)
<223> Sequencing primer for human TNF - forward

<400>  20
tgggagtgag aacctcccaag

<210>  21
<211> 20
<212> DNA
<213> Homo sapiens

<220>
<221> primer_bind
<222> (1)...(20)
<223> Sequencing primer for human TNF - reverse

<400> 21
cttaacggtc cccgtgatttc

<210> 22
<211> 894
<212> DNA
<213> Homo sapiens

<220>
<221> variation
<222> (9)...(743)
<223> LTB*1 (G) polymorphism coding region

<400> 22
cagttcctcaat ggggccacctg gggcttggaag gcaagggatgg gaggggccag gggaggggtat 60
ccccctctgcct acgctgctgca ggaagcccatt cctcctgtgcct gctggctgtg gctggctctat 120
tccctgtctct ggtcctgctgc cccctctggtc cctccaggtca gggagcgact gtaacggaga 180
cgccgaccac cggggcccaac ggcggcccaag gactggggtt tccagacgcc ccaagggagag 240
agccagaaac agatctccag cccgggttccc cagctgccca ccccataggg gtcgctgctga 300
agggggcaggg gctagctggag gagacgcagc aggaacagac agttctgcagc agcccggagcc 360
agttctccga gcgcaagggg ctggcgcctc acgccgagac gcctctgattc ctctcgtgctc 420
tgcttccgctata cgggggcccag gcggccggga cccccagggc gctgctggta 480
cgtcgtccag cttctggtac ggggctgggg cgcgcctcgg gcccgcagcct cccggagtgc 540
tgcttcgagct ggcggagagc gtagctcctg tgcctggacc ggcggagaga caagggctag 600
ggcctctctg gtacacagagc gtggggggtc gcggcctgg gcaagctcgg gggcgagaga 660
gggtgtaagct caacatgagt cacccggata tgtgtagcct gcgcagaggg aagacacttt 720
ttgggggtgt gatgtgggag tggaggaata gatgtgctgc gcgtcaggtgc gtaaatattt 780
gggtggccgga gcgccttgagc cccatggccag tggggaaatat gtagagact gtttggaatat 840
tgatatgaga cctgtagaaata ataaagagat gaaagatctca gtcgctggca taaa 894
### INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

**IPC 7** C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**IPC 7** C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBL, EMBASE

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category *</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

[X] Further documents are listed in the continuation of box C. [X] Patent family members are listed in annex.

* Special categories of cited documents:

**A** document defining the general state of the art which is not considered to be of particular relevance

**E** earlier document but published on or after the international filing date

**L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

**O** document referring to an oral disclosure, use, exhibition or other means

**P** document published prior to the international filing date but later than the priority date claimed

* "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* "A" document member of the same patent family

Date of the actual completion of the international search: 24 February 2005

Date of mailing of the international search report: 10/03/2005

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Authorized officer: Leber, T
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>SMITH ET AL: &quot;Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>XP002099015 ISSN: 0036-8075</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>HOLWEG C T J ET AL: &quot;Clinical impact of cytokine gene polymorphisms in heart and lung transplantation&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2004-09), pages 1017-1026, XP004595231 ISSN: 1053-2498</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>ABRAHAM L J ET AL: &quot;HAPLOTYPIC POLYMORPHISMS OF THE TNFB GENE&quot;</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>LEE BENHUR ET AL: &quot;Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4&quot;</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>WO 02/089796 A (NOVARTIS AG; CHIBOUT, SALAH-DINE; CORDIER, ANDRE; KEHREN, JEANNE; MOOR) 14 November 2002 (2002-11-14)</td>
<td></td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 3888224 T2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0288088 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2001552 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2647427 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5075236 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5885970 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5959096 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5882927 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5922686 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5703054 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5948898 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4847900 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1185696 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002543853 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0070091 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6339066 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6537973 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6153599 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003148989 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6117847 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 710972 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7007198 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 688354 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7398194 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9406931 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2166058 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0714449 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 960089 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 75834 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 8507929 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3553068 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2001224386 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2001231579 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2001224387 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 211424 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 960079 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 269653 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9502069 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5681747 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6015892 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 212063 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 675638 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 3802593 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2132094 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69331467 D1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69331467 T2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 672180 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1126025 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1310555 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0672180 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2170065 T3</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>EP</td>
<td></td>
<td>EP 1389108 A2</td>
</tr>
<tr>
<td>WO 02089796 A2</td>
<td></td>
<td>WO 02089796 A2</td>
</tr>
</tbody>
</table>